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1.  INTRODUCTION  
1.1  Hepatocellular carcinoma  
1.1.1  Epidemiology and risk factors  
Primary liver cancer is the sixth most common cancer worldwide, with more than 
850,000 new cases annually, and it is the second most common cause of cancer-related 
death. The prognosis is very poor, the overall ratio of mortality to incidence is 0.95.1 
Hepatocellular carcinoma (HCC) represents approximately 90 percent of primary liver 
cancer cases. HCC is more common in males, the male/female ratio is about 3-5/1.2 The 
majority of cases occurs after the age of 40, and it reaches a peak at around the age of 70.3 
HCC incidence rates are the highest in areas with endemic hepatitis B virus (HBV) infec-
tion, such as Eastern Asia and sub-Saharan Africa (> 20 per 100,000).4 In particular, 
China accounts for about 50 percent of all HCC cases worldwide.1 Mongolia has the 
world’s highest incidence of HCC with a rate of 78 per 100,000 individuals, about 8 times 
the global average.5 Southern European countries have intermediate incidence rates of 
10-20 per 100,000 individuals. Areas with low incidence (< 5 per 100,000) are found in 
South-Central Asia, North and South America, and Northern, Central, and Eastern Eu-
rope.1, 4 Interestingly, HCC rates are increasing in the low-rate areas, which could be at-
tributed to increases in chronic hepatitis C virus (HCV) infection, obesity, and type 2 
diabetes. In contrast, HCC incidence is decreasing in many high-rate areas, most likely 
because of declining incidence of in HCV and HBV infection.1 
Unlike most cancer types, HCC has well-established environmental and endoge-
nous risk factors.6 In approximately 70 percent of cases, HCC occurs on a background of 
hepatic cirrhosis, whereas in 15-20 percent of cases it develops in non-fibrotic liver or in 
livers with minimal portal fibrosis. Annual incidence rates of HCC in patients with cir-
rhosis are 2-6 percent.7, 8 Major risk factors for developing cirrhosis are chronic HBV and 
HCV infection, half of all HCC cases are associated with HBV infection, with 25 percent 
associated with HCV infection.9, 10 Aflatoxin B1, a mycotoxin present in a variety of food 
commodities in Asia and sub-Saharan Africa, acts in synergism with HBV.11 Heavy al-







cirrhosis and has a synergistic effect with HCV and HBV infection.4 The prevalence of 
metabolic syndrome, a collection of problems, including insulin resistance, obesity, hy-
perlipidemia, and hypertension, is increasing worldwide. It has recently been recognized 
as a risk factor for HCC because of the associated non-alcoholic fatty liver disease and 
non-alcoholic steatohepatitis.12 Other risk factors include anabolic steroids, oral contra-
ceptives, autoimmune hepatitis, cholestatic liver diseases, hypothyreosis, hereditary he-
mochromatosis, and α-1 antitrypsin deficiency.5 
1.1.2  Morphology and histology  
Hepatocarcinogenesis is a multistep process that usually takes place in the context 
of liver cirrhosis. Cirrhosis is characterized by an exhaustion of the regenerative capacity 
of the liver, and the replacement of normal liver tissue by fibrous tissue. The first step of 
HCC development in cirrhotic liver is the appearance of microscopic dysplastic foci (< 1 
mm in diameter). Dysplastic foci are composed of dysplastic hepatocytes and display a 
spectrum of cytologic abnormalities, among which small cell change is regarded as 
premalignant. Dysplastic nodules are macroscopically detectable, distinctly nodular le-
sions (> 1 mm in diameter) that may also appear in chronic liver disease without cirrhosis. 
Dysplastic nodules are classified as low-grade and high-grade dysplastic nodules accord-
ing to the degree of cellular atypia and can be difficult to distinguish from large regener-
ative nodules. High-grade dysplastic nodules are characterized by moderate cytologic or 
architectural atypia and an increased risk of malignant transformation.8, 13  
Based on clinicopathological studies, HCCs can be divided into early and pro-
gressed carcinomas. Early HCCs are small (< 2 cm), vaguely nodular, well-differentiated 
lesions that consist of small neoplastic cells arranged in irregular, thin trabeculae and 
pseudoglandular structures. Invasion into portal tracts and fibrous septa is frequently ob-
served; however, early HCC does not show vascular invasion. Progressed HCCs are 
larger than 2 cm or small (< 2 cm), but moderately differentiated, distinctly nodular le-
sions (Figure 1).13, 14 By gross appearance, progressed HCC can be classified as nodular, 
massive (large tumor with irregular demarcation) and diffuse (many small nodules in a 
lobe or the whole liver). Tumors are generally soft because of lack of a desmoplastic 







nodule are characteristic features of progressed HCC. Vascular invasion with involve-
ment of portal veins is also frequently seen. 
 
Figure 1. Progressed, small hepatocellular carcinoma. Adapted from Park.13 (A) Mac-
roscopic features of progressed, small hepatocellular carcinoma. Note the distinctively 
nodular appearance with tumor capsule in cirrhosis. (B) Microscopic features of moder-
ately differentiated, progressed, small hepatocellular carcinoma. Arrows indicate inva-
sion of the tumor capsule. Hematoxylin-eosin stain, original magnification ×200. 
The WHO describes several histologic patterns of HCC: trabecular (micro- and 
macrotrabecular), acinar (pseudoglandular), solid (compact), and scirrhous. Clear cell 
HCC and fibrolamellar HCC are recognized as rare variants. The most common growth 
pattern is trabecular, where thick cords of neoplastic cells are separated by sinusoids, re-
sembling the cell plates and sinusoids of normal liver. Acinar pattern is characterized by 
gland-like structures formed by dilated bile canaliculi that may contain bile or proteina-
ceous material. Scirrhous HCC (sHCC) is composed of small tumor nests divided by 







from classic HCC. It typically occurs in young adults in a non-cirrhotic liver, has no gen-
der predilection and no known risk factors. Tumor cells in HCC are usually polygonal, 
have eosinophilic, finely granular cytoplasm and hyperchromatic nuclei with prominent 
nucleoli. Mallory-Denk bodies, pale bodies, lipid deposition, glycogen, and bile can also 
be present within the tumor cells.8, 15 
1.1.3  Diagnosis 
In early stages, HCC is usually asymptomatic making clinical diagnosis difficult. 
The majority of patients are diagnosed at an advanced stage with large, symptomatic tu-
mors and/or portal vein invasion. Symptoms and signs include abdominal discomfort, 
jaundice, ascites, hepatic encephalopathy, splenomegaly, fever, anorexia, weight loss, and 
malaise.16, 17 Current clinical guidelines recommend surveillance of HCC in patients at 
risk for HCC. Surveillance involves the repeated application of screening tools to detect 
the disease at an early stage in order to reduce mortality. Surveillance of HCC is recom-
mended in all cirrhotic patients and in some non-cirrhotic patients with chronic liver dis-
ease, especially in HBV carriers with serum viral load > 104 copies/mL or HCV infected 
patients with bridging fibrosis. Surveillance of patients at risk should be carried out by 
abdominal ultrasound every 6 months.16, 18 The measurement of alpha-fetoprotein (AFP) 
or other serum biomarkers alone or in combination with ultrasound is not recommended 
for surveillance.5  
In cirrhotic patients, hepatic nodules smaller than 1 cm are followed by ultrasound 
until further progression, since the likelihood that these small lesions are HCC is low.  
Hepatic nodules larger than 1 cm in diameter are investigated further with multiphase 
contrast-enhanced computed tomography or magnetic resonance imaging. For nodules of 
1-2 cm in diameter, diagnosis is based on characteristic radiological findings (so called 
‘non-invasive criteria’) or biopsy. Nodules larger than 2 cm in diameter can be diagnosed 
as HCC based on characteristic findings on one imaging modality. Typical hallmark of 
HCC is a robust arterial phase enhancement with washout in the portal venous or delayed 
phases. Biopsy is recommended to confirm the diagnosis for cases with inconclusive or 
atypical imaging appearance in cirrhotic livers and for all nodules that occur in non-cir-







architectural and cytologic features can be evaluated in biopsy specimen.21 Negative bi-
opsy result may warrant a second sample if the suspicion of HCC is suffciently strong. 
Pathological diagnosis of HCC is based on the recommendations of the International Con-
sensus Group for Hepatocellular Neoplasia.19, 21 They recommend immunostainings for a 
combination of different markers (glypican 3, heat schock protein 70, and glutamine syn-
thetase) to differentiate high grade dysplastic nodules from early HCC. Additional im-
munostainings for cytokeratin 19 (CK19), epithelial cell adhesion molecule (EpCAM), or 
CD34 can be performed to detect progenitor cell features or assess neovascularisation. 
1.1.4  Molecular pathogenesis 
1.1.4.1  Genetic and epigenetic alterations 
HCC is a complex, genetically and phenotypically heterogeneous malignancy. 
The development of HCC is a slow, multistep process during which genetic and epige-
netic changes in cellular proto-oncogenes and tumor suppressor genes, and subsequent 
disruption of specific pathways progressively alter the hepatocellular phenotype.22 Onco-
gene activation can arise through mutations, copy number alterations, chromosome rear-
rangements, or epigenetic changes; inactivation of tumor suppressor genes can result from 
mutations, loss of heterozygosity, or epigenetic silencing (Table 1).5, 23  
Elucidating the early and late events of hepatocarcinogenesis has gathered mo-
mentum by recent advances in molecular biological techniques, the latest being the next-
generation sequencing technologies. A major goal of large-scale genome sequencing 
studies has been to find cancer driver genes. A cancer driver would be a cell-autonomous 
or non-cell-autonomous alteration that contributes to tumor evolution at any stage by pro-
moting proliferation, survival, invasion, or immune evasion.24 Cancer driver genes are 
defined as those for which the rate of non-silent mutations is significantly greater than a 
background (or passanger) mutation rate estimated from silent mutations.25 Exome se-
quencing analysis of 243 HCCs revealed a median of 64 non-silent and 21 silent muta-
tions per tumor (ranging from 1 to 706 mutations), corresponding to a mean somatic mu-
tation rate of 1.3 mutations per megabase in coding sequences.26 By integration of muta-
tions, focal amplifications, and homozygous deletions, 161 putative driver genes were 
identified. The genetic alterations centered on CTNNB1, AXIN1, and TP53, forming three 







reverse transcriptase (TERT) promoter mutations activating telomerase expression, 
Wnt/β-catenin, PI3K-AKT-mTOR, TP53/cell cycle, mitogen-activated protein kinase 
(MAPK), hepatic differentiation, epigenetic regulation, chromatin remodeling, oxidative 
stress, IL-6/JAK-STAT, and transforming growth factor beta (TGF-β).26  
Table 1. Major genetic alterations observed in advanced hepatocellular carcinoma. 
Adapted from Llovet et al.5 






Promoter mutation 54-60% 
Amplification 5-6% 
Cell cycle  
control 
TP53 Mutation or deletion 12-48% 
RB1 Mutation or deletion 3-8% 
CCND1 Amplification 7% 
CDKN2A Mutation or deletion 2-12% 
Wnt-β-catenin 
signalling 
CTNNB1 Mutation 11-37% 
AXIN1 Mutation or deletion 5-15% 
Oxidative stress 
NFE2L2 Mutation 3-6% 
KEAP1 Mutation 2-8% 
Epigenetic and 
chromatin       
remodelling 
ARID1A Mutation or deletion 4-7% 
ARID2 Mutation 3-18% 
KMT2A (MLL1), KMT2B (MLL4), 






RPS6KA3 Mutation 2-9% 
TSC1 and TSC2 Mutation or deletion 3-8% 
PTEN Mutation or deletion 1-3% 
FGF3, FGF4, and FGF19 Amplification 4-6% 
PI3KCA Mutation 0-2% 
Angiogenesis VEGFA Amplification 3-7% 
ARID, AT-rich interaction domain; AXIN1, axin 1; CCND1, cyclin D1; CDKN2A, cyclin-
dependent kinase inhibitor 2A; CTNNB1, β-catenin; FGF, fibroblast growth factor; HCC, 
hepatocellular carcinoma; KEAP1, kelch like ECH associated protein 1; KMT, lysine (K)-
specific methyltransferase; MAPK, mitogen-activated protein kinase; MLL, mye-
loid/lymphoid or mixed-lineage leukaemia (trithorax homologue, Drosophila); mTOR, 
mammalian target of rapamycin; NFE2L2, nuclear factor, erythroid 2 like 2; PI3K, phos-
phoinositide 3-kinase; PTEN, phosphatase and tensin homologue; RB1, retinoblastoma 1; 
RPS6KA3, ribosomal protein S6 kinase, 90kDa, polypeptide 3; TERT, telomerase reverse 
transcriptase; TP53, cellular tumor antigen p53; TSC, tuberous sclerosis; VEGFA, vascu-







The Cancer Genome Atlas Research Network has recently published the results 
of the first large-scale multi-platform analysis of HCC.27 The most common somatic mu-
tation was TERT promoter mutation, found in 44 percent of all HCC cases. In total, 26 
cancer driver genes were identified, of which 18 were previously reported in various stud-
ies, including TP53, CTNNB1, ALB, AXIN1, APOB, KRAS, and NRAS.5, 26 The most fre-
quent chromosomal arm alterations included copy number gains in 1q and 8q, and copy 
number losses in 8p and 17p. Twenty-eight significantly reoccurring focal amplifications 
and 36 deletions were identified in the tumors. The focal amplifications contained previ-
ously described driver oncogenes such as MCL1 (1q21.3), MYC (8q24.21), CCND1 and 
FGF19 (11q13.3), MET (7q31.2), and VEGFA (6p21.1). Amplification of TERT 
(5p15.33) was found in 10 percent of HCCs. Among the deletions, 13q14.2 (RB1), 9p21.3 
(CDKN2A), 1p36.23 (ERRFI1), and 17p11.2 (NCOR1) were significant.27  
 Epigenetic mechanisms, including covalent modification of DNA and histone 
proteins that changes gene expression without affecting the DNA sequence, are frequently 
deregulated in HCC. Similarly to other cancer types, HCC is characterized by a global 
loss of DNA methylation and selective hypermethylation of gene promoters. Demethyla-
tion largely affects the intergenic and intronic regions of the DNA leading to genomic 
instability. Hypermethylation of CpG islands within gene promoters usually leads to gene 
silencing. Frequent hypermethylation of APC (81.7%), GSTP1 (76.7%), RASSF1A 
(66.7%), CDKN2A (48.3%), PTGS2 (35%), CDH1 (33.3%), DLC1 (24%), and TP53 
(14.2%) have been described.28-30 Moreover, Villanueva et al. identified IGF, PI3K, TGF-
β, and Wnt signaling pathways as clearly deregulated by DNA methylation in HCC.31 
Histone modifications, such as methylation, phosphorylation, acetylation, and ubiquiti-
nation are complex alterations on the amino-terminal tails that can regulate gene expres-
sion by altering chromatin structure or recruiting histone modifiers. 
Significant associations between risk factors and mutations were observed. HCCs 
related to alcohol abuse are significantly enriched in TERT, CTNNB1, CDKN2A, 
SMARCA2, and HGF alterations.26 Hepatitis B virus can induce mutagenesis by inserting 
viral DNA into the genome of hepatocytes.32 Integration of HBV DNA most frequently 
occurs within the TERT promoter and activates telomerase and other oncogenes, includ-







HBV infection, induces DNA adducts and the occurrence of frequent mutations, particu-
larly in TP53.26 In contrast, HCV infection and metabolic syndrome are not associated 
with genetic alterations. 
Genetic alterations associated with the multistep development of HCC have also 
been intensively studied. Marquardt et al. found that the number of exonic somatic muta-
tions with a potentially damaging effect was low in low-grade dysplastic nodules (5), 
high-grade dysplastic nodules (4), and early HCC (2) but drastically increased during 
conversion to progressed HCC (110). Activation of prognostically adverse signaling path-
ways occurred only late during hepatocarcinogenesis and was centered on key oncogenic 
drivers, such as TGFB1, MYC, MET, WNT1, NOTCH1, and pro-metastatic/epithelial-
mesenchymal transition (EMT) genes.34 Similarly, Schulze et al. described progressive 
accumulation of mutations and chromosome aberrations during progression, with chro-
mosome aberrations appearing later than gene mutations.26 TERT activation, that allows 
uncontrolled hepatocyte proliferation, was identified as the earliest recurrent genetic 
event in cirrhotic preneoplastic nodules. 
1.1.4.2  Molecular classification  
Gene expression profiling and analysis of genetic and epigenetic alterations pro-
vided basis for molecular classification of HCC with prognostic implications and poten-
tial targets for targeted therapies. Integration of molecular subclasses reported by different 
investigators revealed that HCCs can be divided into proliferation and non-proliferation 
subtypes, each representing about 50 percent of patients (Figure 2).35-38 
Proliferation subclass is characterized by activation of signaling pathways related 
to cell proliferation and cell cycle progression and is associated with a more aggressive 
phenotype. These pathways include RAS/MAPK, AKT/mTOR, MET, TGF-β, IGF, and 
NOTCH signaling. Notably, this class is also enriched in progenitor cell markers, such as 
EpCAM and AFP. HCCs related to HBV infection predominantly belong to the prolifer-
ation subclass. In the non-proliferation subclass, up to 25 percent of cases are character-
ized by activation of canonical Wnt signaling and CTNNB1 mutations, whereas other 
cases display predominantly inflammation-related traits. Gene expression profiles of tu-
mors in this subclass resemble that of normal hepatocytes. Non-proliferative HCCs are 
less aggressive and frequently associated with human immunodeficiency virus (HIV) in-









Figure 2. Molecular classification of hepatocellular carcinoma. Adapted from Zuc-
man-Rossi et al.38 Proliferation and non-proliferation classes are depicted based on tran-
scriptome profiling with overlapping genetic, epigenetic, and clinical features. AFP, al-
pha-fetoprotein; EpCAM, epithelial cell adhesion molecule; HBV, hepatitis B virus; 
HCV, hepatitis C virus; IGF2, insulin-like growth factor 2; MET, hepatocyte growth fac-








1.2  Secondary liver cancer  
 The liver is one of the most common sites for metastasic disease, which confers 
a bad prognosis, as metastatic lesions disrupt the function of the liver, leading to hepatic 
failure.39 Secondary liver cancers are far more frequent than primary liver cancers, repre-
senting 95 percent of all hepatic malignancies.40 In the majority of secondary liver cancer 
cases, the primary tumors originate from the gastrointestinal tract because of the venous 
drainage of gastrointestinal organs through the hepatic portal system. Other common sites 
of primary tumors include breast, lung, and genitourinary system.41, 42 Histologically, ad-
enocarcinomas are the most frequent subtype of liver metastases, followed by squamous 
cell carcinomas and neuroendocrine carcinomas. Adenocarcinomas are also the most fre-
quent cancer type found in the liver in patients with neoplasms of unknown primary site.43, 
44 
1.2.1  Metastatic process  
The capability to invade adjacent tissues and metastasize is one of the hallmarks 
of cancer.45 The basic steps of metastasis formation has been excessively studied over the 
past century. These include local invasion, intravasation into adjacent vessels, survival of 
the cells in the circulation, extravasation into the surrounding tissue, and initiation and 
growth of metastatic tumors.46, 47 Cancer cells that escaped from the primary tumor can 
enter the liver through the hepatic artery or the portal vein. The arterial and portal blood 
mixes within the hepatic sinusoids, where metastatic cells encounter the liver unique im-
mune defence mechanisms.48 This immune surveillance includes Kupffer cells, liver-spe-
cific natural killer cells, and hepatic sinusoidal endothelial cells. Kupffer cells are liver-
specific macrophages that reside in the wall of the sinusoids.49 Hepatic natural killer cells 
(known as ‘pit cells’ in the rat liver) show morphological similarity to large granular 
lymphocytes and exert cytotoxic activity.50, 51 The interactions with Kupffer cells, natu-
ral killer cells, and hepatic sinusoidal endothelial cells lead to the death of over 90 percent 
of metastatic cells, whereas the surviving cells adhere to the endothelial cells and migrate 
through the hepatic endothelium. Tumor cell invasion into the extrasinusoidal space trig-
ger the activation of hepatic stellate cells and Kupffer cells. Activated hepatic stellate 







(MMPs), produce excessive extracellular matrix proteins, and contribute to neoangiogen-
esis and metastasic growth.52 
Secondary liver cancer classically presents as multiple, well-demarcated, white-
yellow lesions, however, single massive nodules or infiltrative lesions can also be found. 
A fibrous capsule around the metastatic tumor or microcalcifications are infrequently pre-
sent.53 Necrotic areas are often found in the center of large metastatic tumors.  
1.2.2  Colorectal cancer liver metastases 
 Colorectal cancer (CRC) is a common and lethal disease. Globally, it is the third 
most common cancer and the fourth leading cause of cancer-related deaths.54 In Hungary, 
CRC is the second leading cause of cancer death.55 Approximately 20 percent of patients 
have synchronous liver metastasis at the time of diagnosis, and up to 40 percent of patients 
develop metachronous liver metastases.56-58 Development of liver metastases confers a 
poor prognosis,  about 90 percent of  patients who  die  from  CRC  have liver  metasta-
ses.59  
Histologically, over 90 percent of CRCs are adenocarcinomas, variants of which 
include mucinous and signet-ring cell adenocarcinomas.60 Histological subtype has been 
suggested to influence the metastatic pattern of CRC. Mucinous and signet-ring cell ade-
nocarcinoma were more frequently associated with peritoneal than liver metastases.61, 62 
Well and moderately differentiated, columnar shaped metastatic CRC cells form glandu-
lar structures, poorly differentiated liver metastases show almost entirely solid growth 
pattern. Metastatic cells from mucinous or signet-ring cell carcinoma produce abundant 
mucin.   
1.2.3  Pancreatic cancer liver metastases 
Pancreatic cancer is the fourth most fatal cancer worldwide, as well as in Hun-
gary.55, 63 Pancreatic ductal adenocarcinoma (PDAC) arises from the ductal epithelium 
and represents 95 percent of pancreatic cancer cases.64 It has very poor prognosis, the 
incidence and mortality rates are nearly equal. Approximately 50 percent of the patients 
are initially diagnosed with distant metastases. The most common site of metastasis is the 
liver, followed by the peritoneum and lung. At autopsy, about 60 percent of patients had 







65 Microscopically, poorly differentiated metastatic tumors are more frequent than well-
differentiated duct-forming carcinomas. The extensive fibrosis termed desmoplasia that 
occur in primary carcinomas are also observed in metastatic lesions.66  
1.2.4  Differential diagnosis of HCC and metastatic adenocarcinoma  
Differentiating HCC from metastatic adenocarcinoma, especially moderately and 
poorly differentiated HCC from poorly differentiated metastatic adenocarcinoma, and 
identifying the site of origin for metastatic adenocarcinoma can be challenging for 
pathologists. Diagnosis often requires additional immunohistochemical work-up besides 
routine histopathology. Tumor samples can be obtained through image-guided sampling 
using fine needle aspiration and needle core biopsy techniques or surgical resection. Sev-
eral studies aimed to find the most effective immunohistochemical panel that aids in the 
differential diagnosis (Table 2). Ideally, this panel would consist of as few markers as 
possible with high sensitivity and specificity.8, 44, 67  
The most commonly used antibody to identify benign or malignant hepatocytes is 
hepatocyte paraffin 1 (HepPar-1), a monoclonal antibody that recognizes an antigen spe-
cific for hepatocyte mitochondria.68 The sensitivity and specificity of HepPar-1 for HCC 
is over 80 percent.69, 70 However, 50 percent of poorly differentiated sHCCs are negative 
and 20-30 percent of lung, esophageal and gastric adenocarcinomas are positive for Hep-
Par-1. Polyclonal anti-carcinoembryonic antigen (CEA) antibody is highly sensitive for 
HCC and exhibits a specific bile canalicular staining pattern. Alike HepPar-1, it has a 
lower sensitivity in poorly differentiated sHCCs. On the contrary, glypican-3, a cell sur-
face heparan sulfate proteoglycan, shows a higher sensitivity in poorly differentiated 
sHCCs compared to well and moderately differentiated tumors.71 Expression of AFP is 
observed in approximately 30 percent of HCCs but lacking in metastatic adenocarcino-
mas.69 Villin and CD10, similarly to polyclonal anti-CEA, display a bile canalicular stain-
ing pattern specific for HCC. Lack of staining with monoclonal anti-CEA antibody is also 
characteristic of HCCs. Thyroid transcription factor 1 is highly sensitive for HCC and 
exhibits a specific cytoplasmic pattern.72 A monoclonal antibody directed against Ep-
CAM, MOC-31, is highly sensitive and specific for metastatic adenocarcinomas of vari-
ous origin, while HCCs are uniformly negative.70, 73 Caudal type homeobox 2 is an intes-







marker for intestinal adenocarcinomas.43 Cytokeratins are keratin proteins found in inter-
mediate filaments of epithelial cells. Cytokeratins exhibit highly tissue-specific expres-
sion patterns in normal organs and tumors, thus they are useful markers for diagnostic 
histopathology.8, 11 Cytokeratin 7 and CK19 positivity is characteristic of liver metastases 
of pancreatic adenocarcinomas (PLMs), while CK20 is expressed in 70 percent of liver 
metastases of colorectal adenocarcinomas (CRLMs). Most HCC are negative for CK7, 
CK19, and CK20. 








HepPar-1 + - 
Glypican-371 +/- -/rarely + 
AFP +/- - 
CD3470 + - 
TTF-170, 72, 74 + - 
Bile + - 
CD1069, 70, 74, 75 + (canalicular) + 
Villin69, 70 + (canalicular) + 
Polyclonal anti-CEA + (canalicular) + 
Monoclonal anti-CEA69, 75 - + 
CK7/19 -/rarely + +/- 
CK20 - +/- 
CK8/18 + +/- 
CDX2 - + 
MOC-31 - + 
Mucin - + 
-, absent; +/-, may be present; +, usually present. CDX2, caudal type homeobox 2; CEA, 
carcinoembryonic antigen; CK, cytokeratin; HepPar-1, hepatocyte paraffin 1; MOC-1, 
anti-EpCAM antibody; TTF-1, thyroid transcription factor 1. 
1.3  Cancer stem cells 
The cancer stem cell (CSC) model emerged in the 1990s when John Dick dis-







of initiating leukemia when injected into immunocompromised mice. These leukemic 
cells appeared to be abnormal versions of normal adult hematopoietic stem cells that dif-
ferentiate into mature blood cells. Thus, it was suggested that acut myeloid leukemia is 
organized as a hierarchy with many similarities to normal hematopoiesis.76, 77 Other re-
search groups subsequently reported rare populations of cells with tumor-initiating ca-
pacity in a variety of solid tumors, such as brain, lung, breast, ovarian, colon, pancreatic, 
and liver cancers.78-85 
The classical CSC model of tumor heterogeneity proposes that tumors are or-
ganized in a rigid cellular hierarchy that is often reminiscent of the hierarchy in the 
tissue of origin (Figure 3). The bulk of tumor cells that are at the bottom of the hier-
archy are only capable of transient proliferation, therefore do not contribute to long-
term tumor growth and eventually die off. At the top, rare, tipically quiescent CSCs, 
also known as tumor-initiating cells, have the capacity to self-renew (that is, to regen-
erate themselves) and to differentiate into the heterogeneous non-tumorigenic cancer 
cell types that constitute the bulk of the tumor.  
 
Figure 3. The classical cancer stem cell (CSC) model of tumor heterogeneity. 
Adapted from Sugihara and Saya.86 The CSC model states that tumors are composed of a 
hierarchy of cell types, with only a small subset of cancer cells at the top being responsible 
for tumor growth. Upon asymmetric division, CSCs (red) give rise to one CSC and one 
transit-amplifying cell (pink). The latter rapidly amplifies the pool of differentiated cells 







Cancer stem cells have been hypothesized to be the subpopulation that dissem-
inates from the primary tumor, intravasates into the circulation, and metastasizes to 
distant sites.87-90 This is supported by accumulating evidence that CSCs express mark-
ers of EMT, a developmental program frequently activated  during cancer invasion and 
metastasis. Furthermore, induction of EMT in transformed epithelial cells promotes 
the formation of CSCs.91, 92 Cancer stem cells are resistant to conventional cancer treat-
ments, such as chemotherapeutic agents and radiation, partly because these treatments 
selectively kill rapidly dividing non-CSCs - a characteristic that explains relapse after 
treatment. Thus, the CSC theory has important implications for cancer therapy. Devel-
opment of novel therapeutic strategies that target CSCs has become a key goal in the 
challenge to achieve complete eradication of cancer.93, 94  
Various cell surface markers have been associated with CSCs. None of these 
markers are expressed exclusively by CSCs, they can also be present on embryonic stem 
cells (ESCs) (SSEA-1, CD90, CD133, EpCAM, CD24, CD49f, CD29, and CD117), adult 
stem/progenitor cells (LGR5, SSEA-1, CD117, EpCAM, CD133, CD90, CD24, CD29, 
CD49f, and CD44), and normal tissue cells (CD20, CD96, CD29, and CD44).95 CD133 
(Prominin-1), a glycosylated protein with five transmembrane domains, is one of the most 
frequently studied CSC surface marker in solid cancers. It has identified CSCs in liver, 
pancreatic, colon, breast, ovary, prostate, brain, lung, and head and neck cancers in trans-
plantation studies where CD133+ cells generate tumors in immunocompromised mice 
more efficiently than CD133- cells.96 Importantly, antigenic approaches have several 
shortcomings, such as lack of specificity, cross-reactivity, and antibody-dependent tox-
icity. Thus, CSCs cannot be defined based solely on surface markers, marker expression 
has to be linked to functional assays.88 
1.4  Intercellular junctions and claudins 
1.4.1  Intercellular junctions 
Intercellular junctions connect plasma membranes of adjacent cells together. Four 
kinds of intercellular junctions occur in vertebrates: tight junctions, adherens junctions, 
gap junctions, and desmosomes. Adherens junctions are cadherin-based adhesions closely 







the exchange of small metabolites, ions, and second messengers between adjacent cells. 
Desmosomes provide a connection between intermediate filaments of neighboring cells 
conferring stability to tissues that experience mechanical stress.97 
Tight junctions (TJ), the apicalmost part of intercellular junctions, form a circum-
ferential belt at the boundary between the apical and basolateral plasma membrane do-
mains.98 By transmission electron microscopy, TJs appear as a series of close focal con-
tacts or ‘kissing points’ between plasma membranes of adjacent cells. Freeze-fracture 
electron microscopy has revealed a network of continuous, anastomosing TJ strands on 
the protoplasmic face of the plasma membrane with complementary vacant grooves on 
the exoplasmic face (Figure 4).  
 
 
Figure 4. Tight junctions. Adapted from Zihni et al.99 (A) Schematic three-dimensional 
structure of tight junctions. Each tight-junction strand associates with another tight-junc-
tion strand in the opposing membrane of an adjacent cell to occlude the intercellular space 
(kissing point). (B) Freeze-fracture electron microscopy image of tight junction strands 
along the apical membrane of intestinal epithelial cells. 
The number and complexity of TJ strands depend greatly on the cell type and 
correlate with barrier function.100 Tight junctions are composed of a complex assembly 
of transmembrane and peripheral proteins. The main transmembrane proteins are claudins 








mains. Other transmembrane components include a three-transmembrane-domain pro-
tein, BVES, and a large group of immunoglobulin-type adhesion proteins with a single 
transmembrane domain including JAMs, angulins, and CAR. Tricellulin and angulins are 
localized mainly at the tricellular TJs that occur where three cells intersect.99, 101, 102 
Tight junction-associated peripheral membrane proteins function as a bridge be-
tween the transmembrane proteins and the actin cytoskeleton. They include a vast number 
of adaptor proteins that contain multiple protein-protein interaction domains. The most 
important TJ adaptor proteins are members of the MAGUK protein family, ZO-1, ZO-2, 
and ZO-3. MAGUK proteins are recognized for having structurally conserved PDZ, GK, 
and SH3 domains. Other examples of TJ adaptor proteins are cingulin, MUPP1, PATJ, 
and the MAGUK inverted proteins named MAGI. Signaling proteins, such as atypical 
protein kinase C, the Rho family guanosine triphosphatases CDC42, Rac, and RhoA and 
their regulators control the establishment and function of TJs.98, 99  
The two major physiological roles of TJs are the gate and fence functions. By 
constituting semipermeable gates that restrict paracellular diffusion of ions, water, and 
macromolecules, TJs are essential for the maintenance of homoeostasis in organs and 
tissues. Fence function refers to maintenance of cell polarity by blocking free diffusion 
of proteins and lipids between the apical and basolateral plasma membrane domains. 
Apart from their barrier functions, TJs send signals to the cell interior through various 
signaling pathways to regulate cell proliferation, differentiation, and apoptosis.99 Despite 
being heavily cross-linked structures, TJs undergo continuous remodeling at steady state, 
which modulates their different functions.103 Disturbances of TJ function have been 
shown in various diseases. Some of these are inherited diseases, such as velocardiofacial 
syndrome, familial hypercholanemia, or pseudohypoaldosteronism type II. Viral and bac-
terial pathogenes that target TJ proteins include hepatitis C virus, coxsackieviruses, ade-
noviruses, Clostridium perfringens, Vibrio cholerae, and Helicobacter pylori. Chronic 
inflammatory diseases and cancer have also been linked to TJ dysfunction, however, it is 
unclear whether the observed changes are primary or secondary to disease pathogene-







1.4.2  Claudins 
The demonstration that knockout mice for occludin possessed physiologically and 
structurally normal TJs led to the discovery that the backbones of TJ strands were consti-
tuted by claudin proteins.106 Claudins comprise a large gene family, to date, 26 members 
in humans and 27 in mice have been identified.99 Claudin genes are typically small with 
few introns, and many of them lack introns all together. Interestingly, several pairs of 
CLDN genes that are sequence-wise very similar to each other are located close together 
on the same chromosome, suggesting that their evolution was driven by gene duplica-
tion.107  Phylogenetic analyses revealed close relationships among several claudin pro-
teins. High common sequence similarity was detected among CLDN-1-10, -14, -15, -17, 
and -19 in mice, these CLDNs were therefore named ‘classic’ CLDNs.108  
Claudins contain four transmembrane domains, two extracellular loops and short 
intracellular amino-terminal and carboxy-terminal tails (Figure 5). Generally, the amino-
terminal domain consists of 4-5 residues followed by the first extracellular loop of 60 
residues, a short 20-residue intracellular loop, the second extracellular loop of approxi-
mately 24 residues, and a carboxy-terminal tail of 21-63 residues. The amino acid se-
quences of the first and fourth transmembrane domains are highly conserved, whereas the 
second and third exhibit more variability.107 The first extracellular loop determines the 
charge selectivity of paracellular transport because of its charged amino acids.109 The two 
highly conserved cysteine residues in the first extracellular loop form an intramolecular 
disulfide bond to increase protein stability.110, 111 The second extracellular loop has been 
implicated in the formation of dimers between CLDNs of opposing cell membranes by 
virtue of its helix-turn-helix motif conformation.112 The second extracellular loop of sev-
eral CLDNs, including CLDN-3, -4, and -7, also act as a receptor for Clostridium 
perfringens enterotoxin (CPE).113 The carboxy-terminal tail shows the most sequence and 
size heterogeneity among CLDNs. At positions -3, -2, -1, and 0, most CLDNs contain a 
PDZ-binding motif that allows them to directly interact with TJ adaptor proteins ZO-1, -
2, -3, and MUPP1.114, 115 Post-translational modifications, such as palmitoylation and 
phosphorylation by serine/threonine and tyrosine kinases, target the carboxy-terminal tail 
and regulate localization and function of CLDNs.116 For example, phosphorylation of 








Claudins exhibit tissue- and cell-type-specific expression patterns. Multiple 
CLDNs expressed simultaneously at the TJ establish homotypic and heterotypic interac-
tions that allows strand pairing between adjacent cells.119 Heterotypic interactions are re-
stricted to specific combinations of CLDNs. Although CLDN-3 and CLDN-4 are heter-
omerically compatible, they do not heterotypically interact. On the other hand, hetero-
typic interaction has been demonstrated for claudins 1↔3, 2↔3, and 3↔5.120 Claudins 
frequently locate outside the TJ at the lateral membrane, in the cytoplasm, or in the nu-
cleus. Their non-TJ functions include interaction with cell surface receptors, formation of 
unconventional adhesive cell contacts, and intracellular signaling.121  
 
Figure 5. Scheme of claudin structure. Modified from Chiba et al.100 Claudin proteins 
consist of four transmembrane domains, two extracellular domains, and short intracellular 
amino- and carboxy-terminal tails. They interact with tight junction-associated adapter 
proteins that contain PDZ domain through their carboxy-terminal tail. CPE, Clostridium 
perfringens enterotoxin. 
Claudins determine the charge and size selectivity of paracellular transport by 
forming paracellular pores. Permeability properties of a given tissue are largely dependent 
on the combination of CLDNs that are expressed.122 Claudins can be functionally grouped 
according to their barrier- and channel-forming characteristics. Barrier-forming CLDNs 







of water and solutes. Channel-forming CLDNs form paracellular cation pores (CLDN-2, 
-7, -10B, -15, and 16) or anion pores (CLDN-10A).108, 123 Claudins play a key role in the 
pathogenesis of several human diseases. Mutations in four claudin genes (CLDN-1, -14, 
-16, and -19) have been reported to cause hereditary diseases involving ionic imbalance 
in various body compartments.100 Alteration in CLDN expression has been demonstrated 
in various cancer types (Table 3). In particular, CLDN-1, -3, -4, and -7 are among the 
most frequently altered members of the claudin family.124 























Skin, SCC125 ↓ ↑    ↑     
Skin, mela-
noma126 
↑          
Thyroid, 
FTC127 
↑          
Breast ↑↓  ↑↓ ↑↓  ↓     
Lung, SCLC128  ↓ ↑ ↑  ↑     
Lung, AC128 ↓ ↓ ↑ ↑ ↑ ↑     
Lung, SCC128 ↑ ↓ ↓ ↓ ↓ ↑     
Esophagus, 
SCC129 
↑↓   ↓  ↑↓     
Esophagus 
AC130 
 ↑ ↑ ↑       
Stomach ↑  ↑ ↑↓  ↑   ↑↓ ↓ 
Large intestine ↑↓ ↑ ↑ ↑↓ ↑ ↑↓     
Liver, HCC131 ↑↓ ↑   ↑ ↑↓ ↑    
Biliary tract132 ↓ ↓ ↓ ↑  ↑↓ ↓  ↑  
Pancreas, 
DAC133 
↑↓ ↑ ↑ ↑ ↑    ↑  
Pancreas, 
NEC133 
  ↑   ↑     
Bladder    ↑↓       
Kidney ↑  ↑ ↑  ↑     
Prostate ↑  ↑ ↑ ↓ ↑     
Ovary, EOC ↓  ↓ ↑ ↑ ↑  ↑   
Uterine cervix ↓ ↓  ↓  ↓     
Uterine corpus   ↑ ↑  ↓     
AC, adenocarcinoma; CLDN, claudin; DAC, ductal adenocarcinoma; EOC, epithe-
lial ovarian cancer; FTC, follicular thyroid carcinoma; NEC, neuroendocrine carcinoma; 







2.  OBJECTIVES 
In this thesis, I aimed to explore the role that two interconnected concepts recently 
emerged in the field of cancer research - cancer stem cells and altered tight junction pat-
tern - play in the development of HCC, and metastatic liver cancer. The aim of the first 
part of the thesis was to investigate whether the differentiation stage of cells from which 
liver CSCs evolve affects the acquisition of stemness traits and contributes to the genetic 
and phenotypic heterogeneity of HCC. In the second part of the thesis, I aimed to charac-
terize the claudin expression profiles in HCC, and liver metastases of colorectal adeno-
carcinoma and pancreatic adenocarcinoma. My objectives were as follows: 
 
 To assess the ability of mouse hepatic lineage cells at distinct differentiation 
stages (i.e., bipotential hepatic progenitor cells, hepatocyte lineage-committed 
hepatoblasts, and adult hepatocytes) to become cancer stem cells. 
 
 To explore the influence of cell-of-origin on the phenotype of mouse liver tumors 
derived from distinct mouse hepatic lineage cells. 
 
 To identify common and cell-of-origin-specific gene expression signatures in 
mouse liver tumors derived from distinct mouse hepatic lineage cells. 
 
 To investigate the role of c-Myc in the acquisition of cancer stem cell properties 
in adult mouse hepatocytes. 
 
 To characterize the mRNA and protein expression of claudin-1, -2, -3, -4, and -7 











3.  METHODS 
3.1  Plasmid constructs  
I used two lentiviral vectors carrying oncogenes to transform primary hepatic pro-
genitor cells (HPCs), hepatoblasts (HBs), and adult hepatocytes (AHs). Lentiviral vectors 
are very efficient gene transfer tools that integrate into non-dividing and dividing cells.134 
The pSico.FerH-v-H-Ras-IRES-Luc2-EGFP bicistronic lentiviral vector (referred to as 
H-Ras-EGFP) that constitutively expresses oncogenic H-Ras and firefly luciferase/en-
hanced green fluorescent protein (EGFP) double reporter was constructed by Dr. Dominic 
Esposito (Leidos Biomedical Research, Frederick, MD, USA). The v-H-Ras oncogene is 
a highly transforming ras gene, whose encoded protein is constitutively active and differs 
from normal H-Ras protein only at amino acids 12 and 59.135 Bicistronic vectors that 
contain internal ribosome entry site (IRES) element allow the simultaneous expression of 
two proteins separately but from the same messenger RNA.136 The fusion protein of fire-
fly Luciferase2 and EGFP (Luc2-EGFP) combines advantages of a bioluminescent (lu-
ciferase) and a fluorescent (EGFP) reporter. Successfully transduced cells can be identi-
fied by fluorescence microscopy or flow cytometry, and cells expressing luciferase can 
be tracked in vivo by bioluminescence imaging.137 The third-generation HIV-1-based len-
tiviral plasmid pSico (Addgene, Cambridge, MA, USA) was modified for MultiSite Gate-
way recombinational cloning (Thermo Fisher Scientific, Waltham, MA, USA).138  A cas-
sette containing IRES2-Luc2-EGFP was constructed and introduced into the modified 
pSico vector. A ubiquitous FerH promoter (human ferritin heavy chain promoter/SV40 
enhancer) was then inserted allowing ubiquitous, stable expression of v-H-Ras and Luc2-
EGFP.137 The oncogenic H-Ras open reading frame was subcloned from pBW1423 plas-
mid.135  
I constructed the pRRLSIN.cPPT.CAG-SV40LT-IRES-mCherry bicistronic len-
tiviral vector (referred to as SV40LT-mCherry) to constitutively express simian virus 40 
large T antigen (SV40LT) and red fluorescent protein mCherry. Simian virus 40 large T 
antigen, an oncoprotein derived from the polyomavirus SV40, elicits cellular transfor-
mation primarily via inhibition of the p53 and Rb family of tumor suppressors.139-141 The 







pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene), and CAG promoter was inserted.142-144  
Simian virus 40 large T antigen was subcloned from pBabe-puro largeTcDNA 
(Addgene), and an IRES-mCherry cassette was inserted.145  
The pRS retroviral vectors expressing mouse c-Myc short hairpin RNA (shRNA) 
and scrambled negative control shRNA under the U6 polymerase III promoter were kind 
gifts from Dr. James Manley (Columbia University, New York, NY, USA).146 To produce 
viral particles, a second generation packaging vector psPAX2 and an envelope vector 
pCMV-VSV-G were purchased from Addgene.147  
3.2  Production of lenti- and retroviruses  
Lenti- and retroviral expression vectors were propagated in One Shot Stbl3 Chem-
ically Competent Escherichia coli (Thermo Fisher Scientific) using 100 µg/mL carbeni-
cillin at 30°C. Plasmids pCMV-VSV-G and psPAX2 were propagated in DH5α Chemi-
cally Competent Escherichia coli (Thermo Fisher Scientific) at 37°C. Transfection qual-
ity plasmid DNA was isolated by using Plasmid Midi- or Maxi Kit (Qiagen, Valencia, 
CA, USA). Plasmid DNA was verified by agarose gel electrophoresis and restriction anal-
ysis, and concentrations were determined by spectrophotometry. 
Human embryonic kidney (HEK) 293T/17 (American Type Culture Collection, 
Manassas, VA, USA) and HEK 293-GP (Takara Bio, Mountain View, CA, USA) cells 
were used for the production of lenti- and retroviral vector particles, respectively. Cells 
were maintained in high glucose (4.5 g/L) Dulbecco's modified Eagle's medium (DMEM; 
Corning, Corning, NY, USA) supplemented with 4 mM L-glutamine (Thermo Fisher Sci-
entific), 100 units/mL penicillin/streptomycin (Thermo Fisher Scientific), and 10% fetal 
bovine serum (FBS; Corning) in a humidified incubator in an atmosphere of 5% CO2 and 
95% air at 37°C. To produce H-Ras-EGFP and SV40LT-mCherry lentiviral vector parti-
cles pseudotyped with VSV-G envelope, HEK 293T/17 cells were seeded at a density of 
4 × 106 cells per 10-cm tissue culture dish (BD, Franklin Lakes, NJ, USA) and cultured 
for 24 hours (Figure 6). Lentiviral expression vectors (4 µg of each construct) were co-
transfected with pCMV-VSV-G (1.3 µg) and psPAX2 (2.7 µg) by using 24 µL of Li-
poD293 transfection reagent (SignaGen Laboratories, Rockville, MD, USA) in the pres-
ence of high glucose DMEM  supplemented with 4 mM L-glutamine, 10% FBS, and 100 







hours later, filtered through a 0.45 µm filter, and concentrated by ultracentrifugation at 
20,000 rpm for two hours at 4°C. Virus pellet was resuspended in William’s E medium 
(Thermo Fisher Scientific) or DMEM supplemented with 10% FBS and stored at -80°C 
until use. 
 
Figure 6. Production of lentiviral vectors by transient transfection. Modified from 
Shaw and Cornetta.148 Human embryonic kidney (HEK) 293T/17 cells were co-trans-
fected with lentiviral expression vectors H-Ras-EGFP and SV40LT-mCherry, packaging 
vector psPAX2, and envelope vector pCMV-VSV-G. Culture supernatants were collected 
60 hours later, filtered, and concentrated by ultracentrifugation. 
To determine the biological titer of concentrated lentiviral vectors, HeLa cells 
(American Type Culture Collection) were plated at 5 × 104 cells per well in 6-well plates 
(BD) in high glucose DMEM containing 2 mM L-glutamine, 100 units/mL penicil-
lin/streptomycin, and 10% FBS.149 Twenty-four hours later, the number of viable cells in 
two wells was assessed by trypan blue (Thermo Fisher Scientific) exclusion test, and cells 
in the remaining duplicate wells were transduced with various volumes (0.5 μL, 1 μL, 2 
μL, 5 μL, and 10 μL) of lentiviral vector preparations in the presence of 8 µg/mL hexadi-
methrine bromide (Merck, Kenilworth, NJ, USA). After 4 days, cells were detached and 
analyzed on an LSR II flow cytometer (BD) for EGFP or mCherry fluorescence. Dilutions 
yielding 1-20% EGFP- or mCherry-positive cells were chosen for titer calculations. Titers 
were calculated as transducing unit/mL using the following equation, where 1 transducing 
unit is equal to 1 infectious particle: 
Titer =
number of target HeLa cells × % of EGFP+ or mCherry+ cells








To produce VSV-G-pseudotyped retroviral vectors, 3.6 × 106 HEK 293-GP cells 
per 10-cm tissue culture dish were seeded and cultured for 24 hours. HEK 293-GP is a 
293-based cell line stably expressing large quantities of the Moloney murine leukemia 
virus Gag and Pol proteins. Retroviral expression vectors were co-transfected with 
pCMV-VSV-G using LipoD293 transfection reagent in the presence of high glucose 
DMEM, 4 mM L-glutamine, 10% FBS, and 100 units/mL penicillin/streptomycin. Me-
dium was replaced 16 hours after transfection. Vector supernatant was harvested 24 and 
48 hours later, filtered through a 0.45 µm filter, pooled, and used directly upon collection, 
without freeze and thaw.  
3.3  Isolation and transduction of mouse hepatic lineage cells 
I isolated HPCs, HBs, and AHs from C57BL/6NCr mice (Leidos Biomedical Re-
search). Genetically labeled AHs were isolated from B6.Cg-Gt(ROSA)26Sortm14(CAG-
tdTomato)Hze/J mice (The Jackson Laboratory, Bar Harbor, ME, USA). All procedures were 
performed according to protocols approved by the Animal Care and Use Committee at 
the National Institutes of Health (NIH; Bethesda, MD, USA).                                                                                                                    
To induce HPCs, 9-week-old male mice were given a diet containing 0.1% 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC; Bio-Serv, Flemington, NJ, USA) for 2 
weeks.150 Non-parenchymal cells from DDC livers were obtained by a modified two-step 
collagenase perfusion method.151 Liver perfusion catheter was inserted through the right 
atrium into the superior vena cava, and livers were perfused with Hank's balanced salt 
solution (HBSS; Thermo Fisher Scientific) for 5 minutes followed by Williams’ E me-
dium containing 0.05% collagenase type IV (Worthington, Lakewood, NJ, USA) for 10 
minutes at 37°C. Digested livers were removed, minced, and incubated in Williams’ E 
medium containing 0.05% collagenase type IV, 0.05% pronase E (Worthington), and 
0.005% DNase I (Worthington) for 30 minutes at 37°C. Cells were then centrifuged twice 
at 500 rpm for 2 minutes to remove hepatocytes and incubated in hemolysis buffer (16.5 
mM Tris base, 0.1M NH4Cl) containing 10% FBS for 3 minutes on ice. Cell suspensions 
were incubated with a biotinylated antibody against EpCAM (Table 4) and APC Mouse 
Lineage Antibody Cocktail (Table 4) for 30 minutes on ice followed by incubation with 







atopoietic origin. EpCAM+/Lineage Coctail- HPCs were sorted with a FACSVantage in-
strument (BD) and plated in a collagen type I coated 96-well plate (BD) at a density of 
105 cells/cm2 in a basal growth medium supplemented with 50 ng/mL hepatocyte growth 
factor (PeproTech, Rocky Hill, NJ, USA) and 20 ng/mL epidermal growth factor (EGF; 
PeproTech).152 Sorted HPCs from three mice were pooled to form one sample, and four 




anti-actin Merck WB (1:30000) 
anti-AFP Agilent Technologies (Santa Clara, CA, USA)  ICC/IF (1:500) 
anti-albumin Bethyl Laboratories (Montgomery, TX, USA) ICC/IF (1:100) 
anti-A6 Gift from Dr. V. M. Factor154 
FCM (1:100) 
IHC-P (1:40) 
anti-CD29-APC Thermo Fisher Scientific FCM (1:160) 
anti-CD44-APC-Cy7 BD FCM (1:333) 
anti-CD49f-APC Thermo Fisher Scientific FCM (1:333) 
anti-CD90.2-APC Thermo Fisher Scientific FCM (1:333) 
anti-CD133-APC Thermo Fisher Scientific FCM (1:160) 
anti-CLDN-1 Thermo Fisher Scientific IHC-P (1:100) 
anti-CLDN-2 Thermo Fisher Scientific IHC-P (1:100) 
anti-CLDN-3 Thermo Fisher Scientific IHC-P (1:100) 
anti-CLDN-4 Thermo Fisher Scientific IHC-P (1:100) 
anti-CLDN-7 Thermo Fisher Scientific IHC-P (1:100) 
anti-c-Myc Cell Signaling Technology (Danvers, MA, USA) WB (1:1000) 
anti-E-cadherin Takara Bio  
ICC/IF (1:100) 
MACS (1:40) 
anti-EpCAM BD FCM (1:50) 
anti-EpCAM-biotin Gift from Dr. A. Miyajima152 FCM (1:50) 
anti-HNF4a Santa Cruz Biotechnology (Dallas, TX, USA) IHC-P (1:50) 
anti-CK18 




anti-CK19 Developmental Studies Hybridoma Bank 
FCM (1:43) 
IHC-P (1:200) 
anti-laminin Abcam (Cambridge, MA, USA) IHC-P (1:50) 




anti-v-H-Ras Thermo Fisher Scientific 
WB (1:1000) 
IHC-P (1:50) 
anti-vimentin Abcam IHC-P (1:200) 
APC Mouse Lineage Anti-
body Cocktail 
BD FCM (1:5) 
APC, allophycocyanin; BD, Becton Dickinson; FCM, flow cytometry; HNF4a, hepato-
cyte nuclear factor 4 alpha; ICC/IF, fluorescence immunocytochemistry; IHC-P, im-
munohistochemistry on formalin-fixed, paraffin-embedded sample; MACS, magnetic-ac-
tivated cell sorting; SV40LT, simian virus 40 large T antigen; v-H-Ras, Harvey rat sar-







and three biological replicates were collected for microarray and quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR) analysis, repectively.  
 Hepatoblasts were isolated from timed pregnant mice at embryonic day 16.5 by 
magnetic-activated cell sorting (MACS; Miltenyi Biotec, Auburn, CA, USA) using anti-
E-cadherin antibody, clone ECCD2 (Table 4).155, 156 The gestational age of the embryos 
was determined by the number of days after the appearance of the vaginal plug; noon of 
the day on which the vaginal plug was found the embryos were aged 0.5 days.157 Livers 
from littermate embryos were pooled and minced with a scalpel. Minced livers were in-
cubated in 1 U/mL dispase II (Stemcell Technologies, Vancouver, BC, Canada) for 1 hour 
at 37°C with gentle agitation followed by incubation with ACK lysing buffer (Thermo 
Fisher Scientific) and 0.01% DNase I. Up to 107 cells were blocked with 5% normal goat 
serum and incubated with 5 μg of rat anti-mouse E-cadherin antibody for 15 minutes at 4 
oC in MACS buffer containing 1% bovine serum albumin (Thermo Fisher Scientific) in 
phosphate buffered saline (PBS; Thermo Fisher Scientific). After washing, cells were 
mixed with 20 μl of goat anti-rat IgG microbeads (Miltenyi Biotec) in a total volume of 
100 μl and incubated at 4 oC for 15 minutes. Microbeads labeled cell suspension was then 
loaded onto the MS separation column followed by washing twice with MACS buffer. 
Finally, the column was removed from the magnetic field, and E-cadherin+ HBs retained 
in the column were eluted twice with 1 mL MACS buffer as the positively selected frac-
tion. The number of viable HBs was assessed by trypan blue exclusion test. Hepatoblasts 
were plated in collagen type I coated 6-well plates (BD) at a density of 105 cells/cm2 in 
fresh growth medium (DMEM supplemented with 2 mM L-glutamine, 1 mM sodium py-
ruvate, 100 units/mL penicillin/streptomycin, and 10% FBS) mixed 1:1 with conditioned 
medium. Conditioned medium was collected from fetal liver cells cultured without the 
separation of hepatoblasts and non-parenchymal cells, centrifuged at 1000 rpm for 5 
minutes, filtered through a 0.22 μm syringe filter, and stored at −80°C in aliquots. Hepato-
blasts isolated from littermate embryos formed one sample, and four and three biological 
replicates were collected for microarray and qRT-PCR analysis, repectively.  
 Adult hepatocytes were isolated from 3-month-old C57BL/6NCr and B6.Cg-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J male mice by a modified two-step collagenase perfu-
sion procedure.158 Six days prior to hepatocyte isolation, I administered 200 µL of Ad-







centration of 1010 plaque-forming units/mL intravenously via tail vein injection into 
B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J reporter mice to induce hepatocyte-specific 
expression of tdTomato.159 Livers were perfused with HBSS for 5 minutes followed by 
Williams’ E medium containing 0.05% collagenase type I (Worthington) for 15 minutes 
at 37°C. After discoloration of the liver (from dark red to pink) and two-fold increase in 
liver size, digested livers were removed and hepatocytes were combed out in cold hepato-
cyte growth medium.160 After washing, cell suspension was gently overlaid onto equal 
volume of 90% isotonic Percoll solution (Merck) and centrifuged at 1000 rpm for 10 
minutes to separate dead cells from the living ones. Supernatant was discarded, and 
hepatocytes were washed with hepatocyte growth medium. Viable cells were counted 
using trypan blue exclusion test and seeded at a density of 104 cells/cm2 in hepatocyte 
growth medium supplemented with 10% FBS. After 4 hours of attachment, the medium 
was replaced with fresh hepatocyte growth medium. Hepatocytes isolated from one 
C57BL/6NCr mouse formed one sample, and four and three biological replicates were 
collected for microarray and qRT-PCR analysis, repectively. 
 Primary cells were co-transduced with concentrated lentiviruses H-Ras-EGFP 
and SV40LT-mCherry at a multiplicity of infection of 5 (HPCs and HBs) or 10 (AHs) in 
the presence of 6 µg/mL hexadimethrine bromide 24 hours after plating for 12 hours at 
37°C. Multiplicity of infection is defined as the ratio of infectious virus particles (trans-
ducing units) to target cells in a culture. Transduced cells were maintained in their respec-
tive culture medium for 6 days after lentiviral transduction, then cultured for 3 weeks in 
high glucose DMEM containing 2 mM L-glutamine, 1 mM sodium pyruvate, 100 
units/mL penicillin/streptomycin, and 10% FBS to collect a sufficient number of trans-
duced cells from low-frequency HPCs for in vitro and in vivo experiments. H-Ras-
EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs, referred hereafter as T-HPCs, T-HBs, 
and T-AHs, were then sorted with a FACSVantage instrument using the same gating pa-
rameters to ensure comparable viral loads. To obtain single cell-derived clones, T-AHs 
were serially diluted to 10 cells/mL and plated in 96-well plates (BD) at 100 µL/well. 
Twenty-four hours after plating, wells containing single cells were identified and marked. 








For long-term knockdown of c-Myc, T-AHs were transduced with pRS retroviral 
vectors expressing c-Myc shRNA or scrambled shRNA for 16 hours at 37°C. Transduced 
cells were selected with 9 µg/mL puromycin (Merck) for 10 days. Cells transduced with 
c-Myc shRNA vector were sorted into individual wells of a 96-well plate (1 cell/well) 
with a FACSVantage instrument. Expression of c-Myc protein was analyzed by western 
blotting. The following sense shRNA sequences were used: scrambled shRNA, 5’-
GAGGCTTCTTATAAGTGTTTACTCGAGTAAACACTTATAAGAAGCCTCTTTT
T-3’; c-Myc shRNA, 5’-CGGACACACAACGTCTTGGAACTCGAGTTCCAAGACG 
TTGTGTGTCCGTTTTT-3’.146 
3.4  Transplantation mouse models 
 I used male non-obese diabetic/severe combined imunodeficient (NOD/SCID) 
mice between 6 and 9 weeks of age for cell transplantation experiments. Mice were anes-
thetized for 3 minutes with 5% isoflurane (Baxter, Deerfield, IL, USA) in oxygen and 
kept at 2% isoflurane throughout the procedures. All procedures were performed at the 
NIH in accordance with the guidelines of the NIH Animal Care and Use Committee.  
3.4.1  Subcutaneous transplantation 
 For limiting dilution analysis, T-HPCs, T-HBs, and T-AHs (101, 102, or 103 cells 
of each) were mixed 1:1 in DMEM/Matrigel (BD) and injected subcutaneously into both 
flanks (4 mice per group). Tumor formation was monitored weekly by palpation and using 
an external caliper. Mice were euthanized by cervical dislocation 5 weeks after transplan-
tation. Liver, brain, and lungs were removed from each animal and subjected to ex vivo 
bioluminescence imaging. Three million normal HPCs that were injected subcutaneously 
as described above served as negative control. To assess the effect of c-Myc knockdown 
on tumor growth, 102 T-AHs expressing c-Myc shRNA or scrambled shRNA were in-
jected subcutaneously as described earlier (5 mice per group). Animals were monitored 
weekly to detect tumor onset and growth. Tumor dimensions were measured by an exter-
nal caliper, and tumor volume (V) was determined using the following formula: V = l × 







3.4.2  Orthotopic transplantation via direct intrahepatic injection and 
establishment of tumor-derived cell lines 
 To assess orthotopic growth and establish tumor-derived cell lines, T-HPCs, T-
HBs, and T-AHs (1.5 × 105 cells in 40 μl HBSS) were injected into the left liver lobe (5 
mice per group). Surgicel absorbable hemostat (Johnson & Johnson, New Brunswick, NJ, 
USA) was placed over the puncture site, and gentle pressure was applied with a cotton-
tipped applicator to achieve complete hemostasis and prevent leakage of tumor cells. 
Wounds were closed in two layers using 3-0 silk suture and surgical clips. Mice were 
subjected to in vivo bioluminescence imaging twice a week and were euthanized at the 
same time when any of the mice displayed tumor related symptoms. Liver, brain, and 
lungs were removed from each animal and subjected to ex vivo bioluminescence imaging.  
 Primary grafted liver tumors (4 tumors per cell type) were macrodissected and 
washed three times with cold PBS 100 units/mL containing penicillin/streptomycin. Tu-
mors tissues were then finely minced using a sterile scalpel, washed with HBSS supple-
mented with 1 M HEPES (Thermo Fisher Scientific) and 0.2 M EGTA (Merck), and in-
cubated in a shaking water bath at 37°C for 15 minutes. Supernatants were discarded, and 
cell fragments were incubated in collagenase IV for 20 minutes at 37°C followed by a 
digestion with 0.25% trypsin-EDTA (Thermo Fisher Scientific) for 15 minutes. Single 
cell suspensions were diluted in regular culture medium, centrifuged, and plated in 10 cm 
culture dishes (BD). H-Ras-EGFP+/SV40LT-mCherry+ cancer cells were FACS-sorted 
after 3 days of culture. Cells at passage 2 to 5 were used for all in vitro assays.  
3.4.3  Orthotopic transplantation via intrasplenic injection  
 I generated tumor samples for immunochistochemistry and microarray analysis 
by injecting T-HPCs, T-HBs, and T-AHs (105 cells in 20 μl HBSS) intrasplenically to 
ensure tumor formation in the liver from engraftment of a single cell. To calculate the 
probability of tumor initiation by transduced hepatic stem cells (HSCs), we transplanted 
a low number of non-sorted, H-Ras/SV40LT-transduced primary AHs (103 cells) after a 
short-term (1-day) culture. Spleens were removed 30 seconds after the intrasplenic injec-
tion was performed. Wounds were closed in two layers using 3-0 silk suture and surgical 







All mice were euthanized by cervical dislocation when any of the mice displayed symp-
toms of disease, and individual liver tumors were macrodissected. 
3.4.4  Bioluminescence imaging 
 D-luciferin (Biosynth, Itasca, IL, USA) was dissolved in PBS (15 mg/mL) and 
sterile-filtered through a 0.22 µm syringe filter. Mice were anesthetized, injected intra-
peritoneally with 10 µL of luciferin solution per gram of body weight, and placed in the 
imaging chamber of a Xenogen-IVIS-200 Imaging System (PerkinElmer, Waltham, MA, 
USA). Images were acquired 5 minutes after luciferin injection and analyzed using Living 
Image Software v3.0 (PerkinElmer). Bioluminescent signal was expressed as total flux 
(photons per second). After mice were euthanized by cervical dislocation, liver, lungs, 
and brain were dissected and subjected to ex vivo bioluminescence imaging 10 minutes 
after luciferin injection. 
3.5  Flow cytometry  
3.5.1  Analysis of cancer stem cell and hepatic lineage markers 
 I analyzed the expression of hepatic lineage (A6, CK19, and EpCAM) and CSC 
(CD29, CD44, CD49f, CD133, CD90, and Sca-1) markers in normal and H-Ras-
EGFP+/SV40LT-mCherry+ mouse hepatic lineage cells, and tumor-derived cell lines us-
ing antibodies and corresponding isotype controls (Table 4). Viability was assessed by 
staining cells with 4’,6-diamidino-2-phenylindole (Thermo Fisher Scientific). Twenty 
thousand events were recorded on an LSR II flow cytometer configured with FACSDiva 
software (BD). Data analysis was performed with FlowJo software (BD). Each staining 
was performed in triplicate. Data are expressed as mean percentage ± standard deviation. 
3.5.2  Side population analysis       
 The side population (SP) assay is a flow cytometry method based on the ability 
of CSCs to exclude the Hoechst 33342 dye via the ATP-binding cassette (ABC) family 
of membrane transport proteins.161 Normal and H-Ras-EGFP+/SV40LT-mCherry+ mouse 







at 37°C for 90 minutes with 15 µg/mL of Hoechst 33342 dye (Thermo Fisher Scientific) 
in the presence or absence of 50 µmol/l fumitremorgin C (Merck), an ABCG2 inhibitor, 
to identify the SP gate.162 One hundred thousand events were collected on an LSR II flow 
cytometer configured with FACSDiva software. Data analysis was performed with 
FlowJo software. Each assay was performed in triplicate. Data are expressed as mean 
percentage ± standard deviation.   
3.5.3  Nuclear ploidy test 
Nuclear ploidy of normal mouse HPCs, HBs, AHs, and tumor-derived cell lines 
was determined using Cycletest Plus DNA Reagent Kit (BD). Briefly, 5.0 × 105 cells were 
incubated with trypsin-EDTA and ribonuclease A (Merck) at room temperature. Nuclear 
chromatin was stabilized with spermine. Isolated nuclei were stained with cold propidium 
iodide solution at 4°C. Spleen cells from normal adult mice were stained simultaneously 
as a diploid reference. Fifty thousand data events were collected on a FACSCalibur flow 
cytometer (BD) configured with CellQuest Pro software (BD). Data analysis was per-
formed with ModFit (Verity Software House, Topsham, ME, USA). Each assay was per-
formed in triplicate.  
3.6  Sphere formation assay    
 Sphere formation assays are widely used in vitro assays that identify normal stem 
cells and CSCs based on their capacity to self-renew and differentiate.79 A tumorsphere 
is a solid, spherical structure derived from a single CSC. By serial passage of tumorsphere 
cultures, this assay can be used to estimate the frequency of CSCs within a population of 
cancer cells. I tested the ability of normal and H-Ras-EGFP+/SV40LT-mCherry+ mouse 
hepatic lineage cells, and tumor-derived cell lines to form spheroids in adherent-free, se-
rum-free conditions. For each cells type, I seeded 500 cells/well in 10 wells in ultra-low 
attachment 96-well plates (Corning) in serum-free growth medium containing 1% 
methylcellulose (Bio-Techne, Minneapolis, MN, USA), 2% B27 (Thermo Fisher Scien-
tific), 2 mM L-glutamine, 20 ng/mL EGF, and 20 ng/mL basic fibroblast growth factor. 
The growth factors were added fresh every 2 days. The tumorsphere cultures were sub-







with 0.25% Trypsin-EDTA. Viable cells were counted and reseeded in a new 96-well 
plate as described above. Average number and diameters (d1; d2) of spheroids were cal-
culated using ImageJ software (NIH). Spheroid volumes (V) were calculated (in µm3) 
using the following equation: V = d1 × d2
2/2, where d2 designates the shorter diameter. 
Spheroids smaller than 50 µm in diameter were excluded from analysis. Data are pre-
sented as the mean ± standard error of mean of triplicate experiments. 
3.7  Western blot  
Whole cell lysates were prepared from mouse cells using M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific) containing Complete Protease In-
hibitor Cocktail (Roche, Indianapolis, IN, USA). The amount of total proteins was deter-
mined with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Proteins (10 or 50 
µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
transferred onto polyvinylidene difluoride membranes.  The membranes were blocked in 
5% non-fat milk in Tris-buffered saline (Thermo Fisher Scientific) containing 0.1% 
Tween 20 (Thermo Fisher Scientific) for 1 hour and then incubated with primary anti-
bodies against v-H-Ras, SV40LT, and c-Myc overnight at 4°C (Table 4). The secondary 
antibodies were horseradish peroxidase (HRP)-conjugated anti-rat, anti-mouse, and anti-
rabbit (Thermo Fisher Scientific). Immunoreactive bands were visualized using ECL Plus 
Western Blotting Detection Reagent (GE, Chicago, IL, USA). Equal protein loading was 
assessed by probing the same membrane with anti-actin antibody (Table 4).  
3.8  Tissue specimens  
3.8.1  Human tissues  
Formalin-fixed, paraffin-embedded samples from 20 surgically removed HCCs, 
and liver metastases of 20 colorectal adenocarcinomas and 15 pancreatic adenocarcino-
mas with paired surrounding non-tumorous liver tissues were enrolled in the present study 
with the permission of the Regional Ethical Committee of the Semmelweis University 
(#137/2008). Samples were collected at the 2nd Department of Pathology at Semmelweis 







pathologists and further supported by clinical data specific to the location of the primary 
tumor. The median age and female to male ratio in the patient groups were as follows: 65 
years, 7:13 (HCC); 65 years, 7:13 (CRLM) and 58 years, 9:6 (PLM). Five normal liver 
samples from patients who died in accidents were obtained from the Department of Fo-
rensic Medicine at Semmelweis University. 
3.8.2  Mouse tissues 
I generated liver tumors by intrasplenic injection of T-HPCs, T-HBs, and T-AHs 
into NOD/SCID mice as described earlier. Individual tumors (>3 mm in diameter) were 
macrodissected and divided into two portions. One portion of each tumor was frozen in 
liquid nitrogen and stored at -80°C, the remainder was fixed in formalin and embedded 
in paraffin. Semiquantitative histological evaluation and immunohistochemical stainings 
were performed on formalin-fixed, paraffin-embedded tumors (14 HPC-, 28 HB-, and 28 
AH-derived). Frozen tumors were used for microarray analysis (10 HPC-, 20 HB-, and 
20 AH-derived), qRT-PCR (6 samples of each tumor group), and western blotting (2 AH-
derived). 
3.9  Immunostainings and morphometry 
3.9.1  Immunofluorescence stainings  
 To assess the purity of primary mouse HBs, cells were fixed in 4% paraformalde-
hyde (Merck) in PBS for 30 minutes at room temperature. After washing with PBS, cells 
were incubated with PBS containing 1% bovine serum albumin and 0.1% Triton X-100 
(Merck) for 1 hour at room temperature, followed by overnight incubation with primary 
antibodies including E-cadherin, albumin, AFP, and CK18 (Table 4). Alexa Fluor 594-
conjugated rabbit anti-goat IgG, Alexa Fluor 594-conjugated goat anti-rabbit IgG, or 
Alexa 488-conjugated goat anti-rat IgG (Thermo Fisher Scientific) were used as second-
ary antibodies for 30 minutes at room temperature. Nuclei were counterstained with 4’,6-
diamidino-2-phenylindole. Cells were covered with Fluoromount-G mounting medium 
(Thermo Fisher Scientific), and images were acquired on Zeiss LSM 510 NLO (Zeiss, 







3.9.2  Immunohistochemistry on formalin-fixed, paraffin-embedded 
samples  
 Tissues samples were fixed in 10% neutral buffered formalin overnight, embed-
ded in paraffin (FFPE), cut, and stained with hematoxylin and eosin (Merck) for histo-
logical evaluation. Immunohistochemical detection of CLDN-1, -2, -3, -4, and -7, v-H-
Ras, SV40LT, hepatocyte nuclear factor 4 alpha (HNF4a), CK19, laminin, vimentin, and 
A6 was performed on 3-to-4-μm-thick FFPE sections (Table 4). Immunoreactions for 
CLDNs were carried out using the Ventana ES automatic immunostainer (Roche) with 
the streptavidin-biotin-peroxidase technique.128, 163-165 Primary antibodies bound to v-H-
Ras, SV40LT, HNF4a, CK19, laminin, vimentin, or A6 were detected with polymeric 
HRP-conjugated secondary antibodies: Rat-on-Mouse HRP-Polymer Kit (Biocare Medi-
cal, Concord, CA, USA) or Dako EnVision+ System-HRP (anti-mouse or anti-rabbit) 
(Agilent Technologies). All immunoreactions were visualized by 3,3’-diaminobenzidine 
(Merck). For negative controls, specific antibodies were omitted, and either the antibody 
diluent alone or isotype control were used. Positive controls for CLDNs were normal 
human skin epithelium (CLDN-1), human colon mucosa (CLDN-2, -3, and -4), and hu-
man breast ductal cells (CLDN-7). Biliary epithelial cells in normal mouse liver served 
as positive control for CK19 and A6, whereas hepatocytes served as positive control for 
HNF4a. 
3.9.3  Morphometric analysis 
 Reactions of CLDN-1, -2, -3, -4, and -7 in 20 HCCs, 20 CRLMs, and 15 PLMs, 
paired surrounding non-tumorous livers and 5 normal liver samples were subjected to 
morphometrical analysis. Ten non-overlapping images of each FFPE slide were captured 
(×60 objective) using an Olympus BX50 microscope (Olympus Corporation, Tokyo, Ja-
pan). Morphometric analysis of the digital images was performed using Leica QWin 3.0 
morphometrical software (Leica Microsystems Imaging Solutions, Cambridge, UK). 
Claudin expression was measured as percentage of immunopositive pixels relative to the 
total area, which correlates with both the presence and strength of the staining.166 A.H. 







by HCC-, cholangiocarcinoma (CCA)-, and EMT-like phenotypes on hematoxylin-eosin-
stained FFPE sections of 14 HPC-, 28 HB-, and 28 AH-derived tumors.  
3.10  Gene expression studies 
3.10.1  RNA extraction       
  
I used High Pure RNA Paraffin Kit (Roche) to isolate total RNA from manually 
dissected FFPE tissue blocks of 20 HCCs, 20 CRLMs, 15 PLMs, and 5 normal liver sam-
ples. Tumorous and non-tumorous samples were processed separately. I isolated total 
RNA from 16 HPC-, 26 HB-, and 26 AH-derived tumors, and freshly isolated primary 
mouse HPCs, HBs, and AHs (7 samples each) using TRIzol reagent (Thermo Fisher Sci-
entific) in combination with RNeasy Mini Kit (Qiagen). Tumors were histologically ver-
ified prior to RNA isolation to ensure that tumor cells comprised the majority of the sam-
ple. Quantity and purity of total RNA was determined using a Nanodrop ND-1000 Spec-
trophotometer (Thermo Fisher Scientific). I assessed RNA integrity by Agilent 2100 Bi-
oanalyzer (Agilent Technologies). 
3.10.2  Quantitative RT-PCR  
 To measure the relative mRNA expression of CLDN-1, -2, -3, -4, and -7, total 
RNA was reverse transcribed using High Capacity RNA-to-cDNA Kit (Thermo Fisher 
Scientific). Quantitative polymerase chain reaction was perfomed using SYBR Green 
PCR Master Mix (Thermo Fisher Scientific) on an ABI Prism 7000 qPCR machine 
(Thermo Fisher Scientific). Oligonucleotide primers were designed with Primer Express 
software (Thermo Fisher Scientific; Table 5). Relative quantification of target gene ex-
pression was performed using the formula 2∆Ct, where ∆Ct = Ctreference - Cttarget, and β-
actin was used as a reference.  
Validation of microarray results was carried out on an independent set of frozen 
HPC-, HB-, and AH-derived tumors (6 samples of each tumor group), and primary HPCs, 
HBs, and AHs (3 samples each cell type). Total RNA was reverse transcribed using Su-







SYBR Green-based qPCR was performed using the Bio-Rad iCycler Thermal Cycler with 
iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Oli-
gonucleotide primers (Table 5) were obtained from Primer Bank (Harvard University, 
Cambridge, MA, USA) or designed using Primer3 software.167 Relative quantification of 
target gene expression was performed using the above formula, glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh) was used as a reference.  
Table 5. Primers used for quantitative PCR 
Gene 
symbol 
Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
ACTB CCTGGCACCCAGCACAAT GGGCCGGACTCGTCATAC 
CLDN1 GTGCGATATTTCTTCTTGCAGG TTCGTACCTGGCATTGACTGG 
CLDN2 CTCCCTGGCCTGCATTATCTC ACCTGCTACCGCCACTCTGT 
CLDN3 CTGCTCTGCTGCTCGTGTCC TTAGACGTAGTCCTTGCGGTCGTAG 
CLDN4 GGCTGCTTTGCTGCAACTGTC GAGCCGTGGCACCTTACACG 
CLDN7 CATCGTGGCAGGTCTTGCC GATGGCAGGGCCAAACTCATAC 
Gapdh CCACCCAGAAGACTGTGGAT CACATTGGGGGTAGGAACAC 
Afp CCAGGAAGTCTGTTTCACAGAAG CAAAAGGCTCACACCAAAGAG 
Alb AGCACAAGCCCAAGGCTAC TGCATCTAGTGACAAGGTTTGG 
Ednra AGTATGCCTGAGACTTCCAG GTCATCACTGTAGGAGAAACTG 
Flt1 GAGGAGGATGAGGGTGTCTATAGGT GTGATCAGCTCCAGGTTTGACTT 
Mmp12 CATGAAGCGTGAGGATGTAGAC TGGGCTAGTGTACCACCTTTG 
Mmp13 CTATCCCTTGATGCCATTACCAG ATCCACATGGTTGGGAAGTTC 
Pdgfra GGAGACTCAAGTAACCTTGCAC TCAGTTCTGACGTTGCTTTCAA 
Pdgfrb GACTTGGAGTGACAGTGAGT CTTCCTCTCATTGCCCATCT 
Vim CTTGAACGGAAAGTGGAATCCT GTCAGGCTTGGAAACGTCC 
Zeb2 AAAGCGTTCAAACACAAACACC CCGCTTGCAGTAGGAGTACC 
Human gene symbols are italicized written in all uppercase letters, mouse gene symbols 
are italicized, with only the first letter in upper case. ACTB, β-actin; Alb, albumin; Ednra, 
endothelin receptor type A; Flt1, Fms-related tyrosine kinase 1; Gapdh, glyceraldehyde-
3-phosphate dehydrogenase; Mmp, matrix metalloproteinase; Pdgfr, platelet-derived 
growth factor receptor; Vim, vimentin; Zeb2, zinc finger E-box-binding protein 2. 
3.10.3 Microarray 
 Ten HPC-, 20 HB-, and 20 AH-derived tumors, and their normal counterparts (4 
samples each) were subjected to microarray analysis. Linear amplification of 400 ng RNA 
was performed using Illumina TotalPrep RNA Amplification Kit (Thermo Fischer Scien- 
tific). Reactions were incubated at 37ºC for 16 hours for in vitro transcription. Biotinyl-
ated complementary RNA (750 ng/sample) was then hybridized onto MouseRef-8 v2.0 







washing and staining with Cy3-Streptavidin conjugate (GE Healthcare), BeadChips were 
scanned on an Illumina iScan System (Illumina).  
3.11  Statistical analysis 
Lilliefors and Pearson normality tests were used to assess the normality of data. 
Non-parametric tests were used to analyze non-normal data. Significant differences in the 
number of spheres formed by normal and H-Ras-EGFP+/SV40LT-mCherry+ mouse he-
patic lineage cells were evaluated by Poisson generalized linear model. Frequency of tu-
mor-initiating cells in T-AHs, T-HBs, and T-HPCs was calculated and compared using 
Poisson distribution statistics 5 weeks after transplantation. The probability of tumor ini-
tiation by transduced HSCs was calculated using binomial distribution. Significant dif-
ferences in the proportion of HCC-, CCA-, and EMT-like phenotypes in mouse liver tu-
mors were calculated by one-way analysis of variance and Tukey post hoc test. Effect of 
c-Myc knockdown on the kinetics of subcutaneous tumor growth and sphere formation 
was evaluated by Student’s t-test and Poisson generalized linear model, respectively. 
Kruskal-Wallis and post hoc tests were conducted to compare the protein and mRNA 
expression of individual claudins in the different groups; the surrounding non-tumorous 
livers were treated as one group. Statistical analysis was performed using Statistica 8.0 
software (Dell, Round Rock, TX, USA), GraphPad Prism 5.0 software (GraphPad Soft-
ware, La Jolla, CA, USA) or L-Calc software (Stemcell Technologies). P < 0.05 was 
considered significant in all the analyses described above. 
Microarray image analysis and data extraction were performed using Illumina Ge-
nomeScan software (Illumina). Gene expression values were adjusted by subtracting 
background noises in each spot and normalized by quantile normalization method with 
GenomeStudio software (Illumina). All microarray data were submitted to GEO (acces-
sion number GSE41312) and are accessible at http://www.ncbi.nlm.nih.gov/geo/. Tran-
scriptomic similarities between tumors and their normal counterparts were identified us-
ing bioequivalence test.168 Significant differences in gene expression (fold change > ±2; 
P < 0.001) between tumors and their corresponding cell-of-origin were determined by 
bootstrap t-test with 5,000 repetitions.169 Overlap of differentially expressed genes in 
HPC-, HB-, and AH-derived tumors with a core embryonic stem cell module map con-







performed by Ingenuity Pathway Analysis tool 8.7 (Qiagen). Gene set enrichment analy-
sis (GSEA) was performed using GSEA software provided by the Broad Institute (Cam-
bridge, MA, USA). Gene set enrichment analysis is a commonly applied method that 
determines whether an a priori defined gene set shows statistically significant, concordant 
differences between two biological states.171 Statistical significance of the enrichment 
score for a single gene set was estimated by nominal P value. False positives were calcu-
lated by the false discovery rate (FDR). Gene sets with a nominal P value < 0.05 and FDR 
< 0.25 were considered significantly enriched. Enrichment of a 35-gene EMT signature, 
a hepatocyte-derived induced pluripotent stem cell (iPSC) signature of 786 genes, and 
229 Myc E-box target genes was tested in HPC-, HB-, and AH-derived tumors.172-174 
Mann-Whitney U test was used to analyze the expression of genes selected for validation 












4.  RESULTS 
4.1  Contribution of distinct mouse hepatic lineage cells to the 
evolution of liver cancer stem cells and heterogeneity of HCC  
4.1.1  H-Ras/SV40LT reprogram mouse hepatocyte lineage cells into 
cancer stem cells 
 Activation of Ras pathway and disruption of p53 and retinoblastoma pathways 
frequently occur in rodent and human HCCs.175-177 Thus, my experimental approach was 
as follows: isolation of primary mouse hepatic lineage cells at different stages of differ-
entiation, followed by co-transduction with oncogenic H-Ras-Luciferase/EGFP and 
SV40LT-mCherry lentiviral vectors.  
 Hepatic progenitor cells are considered to be the progeny of adult hepatic stem 
cells that differentiate into hepatocytes and cholangiocytes in severely injured liver. They 
express markers in common with cholangiocytes, and fetal and adult hepatocytes.178 I 
isolated HPCs from livers of DDC-treated mice by FACS using anti-EpCAM antibody 
(Figure 7).  
 
Figure 7. Purification of primary mouse hepatic progenitor cells. High purity, epithe-
lial cell adhesion molecule (EpCAM)+/Lineage Antibody Cocktail- hepatic progenitor 
cells were isolated by fluorescence-activated cell sorting. PE, phycoerythrin. 
 
 Hepatoblasts are common progenitors of hepatocytes and cholangiocytes in the 
fetus.179 In mice, the majority of hepatoblasts are committed towards hepatocyte lineage 







16.5 by MACS using a monoclonal antibody against E-cadherin, a specific surface marker 
of immature hepatocytes. I obtained fully differentiated adult hepatocytes from 3 month-
old male mice using a two-step collagenase perfusion method. Next, I analyzed the purity 
of freshly isolated HBs, HPCs, and AHs. Over 99% of the isolated HBs expressed E-
cadherin, AFP, an early marker of hepatocytic differentiation, and albumin, another spe-
cific marker of hepatic lineage cells (Figure 8).156, 181 Reflecting high purity, only isolated 
HBs expressed AFP, whereas AHs exhibited the highest levels of albumin, as measured 
by qRT-PCR (Figure 9).  
 
Figure 8. Immunostaining of primary mouse hepatoblasts after magnetic cell sort-
ing. Purity of purified hepatoblasts was determined by fluorescence immunocytochemis-
try for E-cadherin, AFP, albumin, and CK18 after overnight incubation of primary cul-
tures. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Scale bar 
= 20 µm. 
I co-transduced the cells with H-Ras-EGFP and SV40LT-mCherry lentiviruses 24 
hours after isolation. The infection efficiency was measured by flow cytometry as the 
percentage of EGFP and mCherry double positive cells 10 days after infection. To test 
the properties of the resulting cell populations both in vitro and in vivo, EGFP+/mCherry+ 
HPCs, HBs, and AHs were FACS sorted using the same gating parameters to ensure com-








Figure 9. Quantitative RT-PCR analysis with primers specific to hepatic lineage 
cells. Data are presented as mean expression levels ± standard deviation of AFP and al-
bumin in freshly isolated primary cells relative to glyceraldehyde-3-phosphate dehydro-
genase. All experiments were performed in duplicate using three independent cell isola-
tions. AH, adult hepatocyte; HB, hepatoblast; HPC, hepatic progenitor cell. 
 
Figure 10. Efficient transduction of primary mouse hepatic lineage cells with H-Ras-
EGFP and SV40LT-mCherry lentiviral vectors. Primary HPCs, HBs, and AHs were 
co-transduced with H-Ras-EGFP and SV40LT-mCherry lentiviruses 24 hours after plat-
ing. Transduction efficiency was measured by flow cytometry as the percentage of 
EGFP+/mCherry+ cells 10 days after co-transduction. Transduced cells were sorted using 
the same gating parameters (boxed areas) for further analysis. EGFP, enhanced green 










Figure 11. Western blot analysis of H-Ras and SV40LT protein expressions in H-
Ras-EGFP+/SV40LT-mCherry+ mouse hepatic lineage cells. Primary HPCs, HBs, and 
AHs were ex vivo co-transduced with H-Ras-EGFP and SV40LT-mCherry lentiviruses. 
EGFP+/mCherry+ cells were sorted 10 days after co-transduction and subjected to western 
blot analysis. Actin was used as loading control.  
 All three types of hepatic lineage cells were effectively transformed by H-
Ras/SV40LT and acquired CSC properties as defined by an increase and/or acquisition 
of SP fraction, CD133 expression, and ability to grow as self-renewing spheres (Figures 
12 and 13).80, 83, 92 
 
Figure 12. Flow cytometric analysis of side population cells in normal and H-Ras-
EGFP+/SV40LT-mCherry+ mouse hepatic lineage cells. Side population (SP) cells 
were identified in (A) normal and (B) transduced HPCs, HBs, and AHs by Hoechst 33342 
(HO) staining. SP gates were drawn by using fumitremorgin C (dot plots at the bottom). 


























































































































Figure 13. Analysis of CD133 expression and sphere forming ability in normal and 
H-Ras-EGFP+/SV40LT-mCherry+ mouse hepatic lineage cells. (A) CD133 expression 
was measured by flow cytometry. Blue line indicates APC-conjugated anti-CD133 anti-
body, red line indicates isotype control. Data represent mean ± standard deviation per-
centages of positive cells in three experiments. (B and C) Spheroid forming ability. 
Freshly isolated normal (B) and transduced (C) mouse hepatic lineage cells were cultured 
in 1% methylcellulose in 96-well ultra-low attachment plates at low density. Spheroids 
were counted on day 7. Data represent mean ± standard deviation of four experiments. 
Significant differences were evaluated by Poisson generalized linear model and one-way 
analysis of variance; P < 0.05 was considered statistically significant. *P < 0.05; ***P < 
0.001. 
To quantify the frequency of tumor-initiating cells in each transduced cell popu-
lation, I next performed a limiting dilution assay. The frequency of tumor initiating cells 
within each transplanted cell population was calculated based on the number of palpable 
tumors per number of injections at each transplant dose. Interestingly, the frequency of 
tumor-initiating cells was significantly higher in T-HPCs as compared to T-HBs and T-



































































































































































































































and T-AHs (0/8) by 5 weeks after subcutaneous transplantation (Table 6). In contrast, 
subcutaneous injection of 3 million normal HPCs did not generate tumors after 6 months. 
Ex vivo bioluminescence imaging revealed that tumors initiated by T-HPCs, T-HBs, and 
T-AH were very aggressive and gave rise to multiple metastatic foci throughout liver, 
lungs, and brain with a slightly higher frequency in the recipients of T-HPCs (Figure 14, 
Table 7). 
Table 6. Limiting dilution analysis  
Transformed 
cell type 
Number of injected cells 
TIF 95% CI 
P (comparison 
with HPC) 1000 100 10 
HPC 8/8 8/8 6/8 1/7 1/3 – 1/17 - 
HB 8/8 8/8 2/8 1/26 1/11 – 1/62 0.04 
AH 8/8 8/8 0/8 1/42 1/19 – 1/91 0.003 
H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs were sorted and injected subcu-
taneously into both flanks of NOD/SCID mice (4 mice/group). Frequency of tumor-initi-
ating cells (TIF) was calculated 5 weeks after transplantation based on the number of 
palpable tumors per number of injections at each transplant dose. Significant differences 
were evaluated using Poisson distribution statistics; P < 0.05 was considered statistically 
significant. CI, confidence interval. 
 
Figure 14. Subcutaneous tumor growth and metastatic ability. One hundred cells of 
H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs were injected subcutaneously 
into both flanks of NOD/SCID mice (4 mice/group). (Left panel) Representative in vivo 
bioluminescence image of a mouse 5 weeks after injection of hepatic progenitor cells. 









Table 7. Incidences of primary grafted and metastatic tumors 5 weeks after subcu-






Intrahepatic Lung Brain 
HPC 8/8 (100%) 4/4 (100%) 2/4 (50%) 3/4 (75%) 
HB 8/8 (100%) 4/4 (100%) 2/4 (50%) 3/4 (75%) 
AH 8/8 (100%) 4/4 (100%) 3/4 (75%) 3/4 (75%) 
One hundred cells of H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs were in-
jected subcutaneously into both flanks of NOD/SCID mice (4 mice/group). Metastases 
were identified using ex vivo bioluminescence imaging 5 weeks after injection. 
I obtained similar results in an independent orthotopic transplantation experiment 
when I injected transduced cells of each genotype into the left liver lobe of immuno-






Figure 15. Orthotopic tumor growth and metastatic ability. (A) Representative in vivo 
bioluminescence images of mice 11 days after orthotopic transplantation of 1.5 × 105 cells 
of H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs into the left liver lobe of 
NOD/SCID mice (5 mice/group). (B) Ex vivo bioluminescence imaging of the liver, 

























Transformed cell type Grafted tumor
Metastasis
HPC 5/5 (100%) 5/5 (100%) 5/5 (100%) 3/5 (60%)
HB 5/5 (100%) 4/5 (80%) 5/5 (100%) 2/5 (40%)








Number of injected cells
TIF CI95%
Comparison
with HPC 1000 100 10
HPC 8/8 8/8 6/8 1/7 1/3 – 1/17 -
HB 8/8 8/8 2/8 1/26 1/11 – 1/62 p=0.04
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HPC 5/5 (100%) 5/5 (100%) 5/5 (100%) 3/5 (60%)
HB 5/5 (100%) 4/5 (80%) 5/5 (100%) 2/5 (40%)








Number of injected cells
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Comparison
with HPC 1000 100 10
HPC 8/8 8/8 6/8 1/7 1/3 – 1/17 -
HB 8/8 8/8 2/8 1/26 1/11 – 1/62 p=0.04
















Intrahepatic Lung Brain 
HPC 5/5 (100%) 5/5 (100%) 5/5 (100%) 3/5 (60%) 
HB 5/5 (100%) 4/5 (80%) 5/5 (100%) 2/5 (40%) 
AH 5/5 (100%) 4/5 (80%) 4/5 (80%) 3/5 (60%) 
H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs were injected into the left liver 
lobe of NOD/SCID mice (5 mice/group). Metastases were identified using ex vivo 
bioluminescence imaging 16 days after transplantation. 
To gain greater insight into the tumorigenicity of H-Ras/SV40LT-transformed 
hepatic lineage cells, I established and characterized several clonal cell lines (4 per cell 
type) from tumors generated by direct intrahepatic injection. Irrespective of tumor cell-
of-origin, all established primary tumor cell lines expressed hepatic progenitor/biliary cell 
(CK19, EpCAM, A6) and CSC-associated markers (CD133, CD44, CD29, CD49f, CD90, 
Sca-1), had comparable size of SP fraction, and possessed high self-renewal capacity 
through 6 serial passages (Figures 16 and 17).80, 83, 182  
Collectively, these results indicate that any hepatic lineage cell, including 
terminally differentiated hepatocyte, was susceptible to oncogene-driven transformation. 
Each H-Ras/SV40LT-transformed cell population acquired similar attributes of liver 
CSCs producing aggressive liver cancer with a strong potential for intrahepatic and 
distant organ metastasis. However, primitive HPCs were more susceptible to transforma-









Figure 16. Flow cytometric characterization of mouse hepatic lineage cell-derived 
tumor cell lines. H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs (1.5 × 105 of 
each cell type) were grafted into the left liver lobe of NOD/SCID mice. The resulting liver 
tumors were macrodissected and dissociated to establish tumor cell lines (4/cell type). 
Tumor cells at passage 2 to 5 were used for flow cytrometric assays. (A and B) Analysis 
of liver progenitor/biliary cell (A) and CSC-associated (B) markers.  Blue lines represent 
reactivity for the specified antibodies, red lines correspond to the staining obtained with 
isotype control anti-bodies. Data represent mean ± standard deviation percentages of 
positive cells in four tumor cell lines. (C) Analysis of side population cells. Side 
population cells were identified by Hoechst 33342 staining and the use of blue and red 
filters. Fumitremorgin C was used to set up the SP gate (dot plots shown at the bottom). 










Figure 17. Analysis of spheroid-forming ability of mouse hepatic lineage cell-derived 
tumor cell lines. H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs (1.5 × 105 of 
each cell type) were grafted into the left liver lobe of NOD/SCID mice. The resulting liver 
tumors were macrodissected and dissociated to establish tumor cell lines (4/cell type). 
Tumor cells at passage 2 to 5 were used for sphere formation assay. Cells were plated at 
low density in 1% methylcellulose in 96-well ultra-low attachment plates to generate pri-
mary spheroids that were passaged every 7 days for 6 weeks. Data represent mean ± 
standard error of mean from four tumor cell lines. Phase contrast and fluorescence images 
of spheroids at passage 6 demonstrate stable expression of transgenes. Scale bar = 100 
µm. 
4.1.2  Unambiguous oncogenic reprogramming of adult hepatocytes 
Hepatic stem cells represent an extremely rare population of cells in adult mouse 
liver that reside within the terminal bile ductules surrounded by a basal lamina.183, 184 
Although the protocol for isolation and purification was optimized for primary AHs, it 
could not be ruled out that occasional contaminating HSCs were targeted by H-Ras and 
SV40LT and selectively amplified during a subsequent 3-week growth in culture. To test 
this possibility, I used three experimental approaches. First, I injected a low number of 
H-Ras-/SV40LT-transduced AHs (103 cells) into the spleen of NOD/SCID mice, and 
compared the number of the generated liver tumors with the estimated number of HSCs 
in normal adult mouse liver. To prevent the possibility of selective overgrowth of HSCs, 
H-Ras/SV40LT-transduced primary AHs were transplanted via spleen into NOD/SCID 
mice after a short-term (1-day) culture. Transplanted cells yielded 2-3 liver tumors per 
mouse by 18 days after injection. Our previous findings and literature reports indicated 
that the frequency of EpCAM+ non-parenchymal cells in primary AH culture was on av-
erage 0.13%, and only 0.16% of this fraction possessed sphere forming potential and abil-
ity to differentiate along hepatocytic or biliary epithelial cell lineages.152, 185 Thus, the 
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hepatocytes. Assuming 100% efficiency of transduction and transformation, the proba-
bility of tumor initiation by transduced HSCs is negligible (≤ 2.1 × 10-6; Figure 18).   
 
Figure 18. Overview of the approach used to compare the number of resulting tu-
mors with the estimated frequency of hepatic stem cells (HSCs). Primary adult hepato-
cytes were transduced and then cultured only for 1 day to exclude the possibility of se-
lective overgrowth of HSCs. A total of 1000 transduced cells were injected via the spleen 
into NOD/SCID mice, and liver tumors were counted after 18 days. Probability of tumor 
initiation by transduced HSCs was calculated using binomial distribution.  
Next, I evaluated the in vivo tumorigenicity of genetically labeled, H-
Ras/SV40LT-transduced AHs following a short- (1-day) or long- (21-days) term culture. 
I isolated and transduced primary AHs from homozygous B6.Cg-Gt(ROSA)26Sortm14(CAG-
tdTomato)Hze/J Cre-reporter mice.186 These mice harbor a targeted mutation of 
the Gt(ROSA)26Sor locus with a loxP-flanked STOP cassette preventing transcription of 
a downstream red fluorescent protein, tdTomato. Upon adenoviral delivery of Cre recom-
binase in vivo, the STOP cassette is deleted only in hepatocytes, resulting in expression 
of tdTomato (Figure 18, left panel). Regardless whether transduced AHs were maintained 
in vitro for 1 day or 21 days, the number of liver tumors initiated after the transplantation 
of 105 AHs were not significantly different: 7.3 (5-11) and 6 (5-7), respectively. Ex vivo 
imaging of dissected livers confirmed that all tumors displayed overlapping luciferin and 
tdTomato signals indicating that the tumors originated from AHs (Figure 19, right panel). 
 Lastly, I found a significant increase in nuclear ploidy in cell lines derived from 
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Figure 19. Generation of liver tumors from genetically labeled adult hepatocytes. 
(Left panel) Phase contrast and fluorescence images of 24-hour primary AH culture 
established from B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J mouse. Isolated AHs 
showed strong, homogeneous expression of tdTomato 1 week after intravenous injection 
of adenovirus-Cre. Circle marks tdTomato-negative non-parenchymal cells. Scale bar = 
100 μm. (Right panel) Ex vivo bioluminescence and fluorescence images of livers 18 days 
after injection of 105 hepatocytes co-transduced with H-Ras-EGFP and SV40LT-mCherry 
lentiviruses. Transduced AHs were cultured for 1 or 21 days before intrasplenic trans-
plantation.  
 
Figure 20. Flow cytometric analysis of DNA content of mouse hepatic lineage cell-
derived tumor cell lines. DNA content of clonal cell lines (4/cell type) from tumors gen-
erated by direct intrahepatic injection of H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, 
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isolated from HPC tumors were predominantly diploid, similarly to normal HPCs. Taken 
together, these results demonstrate that terminally differentiated AHs but not contaminat-
ing HSCs were the targets of oncogenic transformation. 
4.1.3  H-Ras/SV40LT induce liver cancer of multilineage differentiation  
To assess the impact of cell-of-origin on tumor histopathology, I injected H-
Ras/SV40LT-transduced HPCs, HBs, and AHs into the spleens of NOD/SCID mice to 
ensure tumor formation from engraftment of a single cell. For comparison, 14 HPC-, 28 
HB-, and 28 AH-derived individual tumors were macrodissected and subjected to mor-
phometrical and immunohistochemical analyses. Cancer cells exhibited strong submem-
branous staining for H-Ras and nuclear staining for SV40LT, confirming that the tumors 
indeed originated from H-Ras/SV40LT-expressing cells (Figure 21).  
 
Figure 21. Expression of H-Ras and SV40LT in different tumor phenotypes. Im-
munohistochemical detection of v-H-Ras and SV40LT was performed on formalin-fixed, 
paraffin-embedded sections of liver tumors generated by intrasplenic injection of H-Ras-
EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs. Reactions were visualized by 3,3’-dia-
minobenzidine. Mayer’s hematoxylin was used as nuclear counterstain. CCA, cholangi-
ocarcinoma; EMT, epithelial-mesenchymal transition; HCC, hepatocellular carcinoma. 








Irrespective of cell-of-origin, tumors were moderately to poorly differentiated 
with varying contribution of EMT-, CCA-, and HCC-like phenotypes supporting the con-
cept of continuous spectrum of human primary liver cancer (PLC; Figures 22 and 23).174 
Semiquantitative analysis revealed a dominant EMT-like phenotype (85.0 ± 18.2% of the 
tumor cross-section areas) in HPC-derived tumors consisting of sheets of spindle-shaped, 
mesenchymal-like cancer cells. HB-derived tumors showed mostly CCA-like phenotype 
(52.7 ± 37.8%) composed of heterogeneous, columnar or cuboidal cancer cells arranged 
in glandular and tubular structures surrounded by abundant fibrous stroma. AH-derived 
tumors predominantly displayed an HCC-like phenotype (59.7 ± 34.6%) of polygonal, 
hepatocyte-like tumor cells arranged in solid pattern (Figure 23). 
 
Figure 22. Semiquantitative analysis of EMT-, CCA-, and HCC-like tumor pheno-
types. Circle graphs represent the mean percentage of tumor areas occupied by HCC-, 
CCA-, and EMT-like phenotypes in liver tumors generated by intrasplenic injection of H-
Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs. Significant differences were eval-
uated by one-way analysis of variance. P < 0.05 was considered statistically significant. 
The majority of HCC-like tumor cells expressed HNF4A, a central mediator of 
hepatocyte differentiation.188 Cholangiocarcinoma- and EMT-like tumor cells were also 
positive for HNF4A albeit with lower frequency. I observed strong, uniform expression 
of progenitor/biliary cell markers keratin 19 and A6 regardless of tumor cell-of-origin. 
Furthermore, EMT- and HCC-like tumor cells showed intense cytoplasmic and extracel-
lular staining for laminin, a component of the hepatic progenitor cell niche in rodent and 
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Figure 23. Immunohistochemical characterization of EMT-, CCA-, and HCC-like 
tumor phenotypes. Liver tumors were generated by intrasplenic injection of H-Ras-
EGFP+/SV40LT-mCherry+ hepatic progenitor cells, hepatoblasts, and adult hepatocytes. 
Reactions were visualized by 3,3’-diaminobenzidine. Mayer’s hematoxylin was used as 
nuclear counterstain. Red marks indicate transduction with H-Ras/SV40LT lentiviral vec-







To confirm that the EMT-, CCA-, and HCC-like tumor phenotypes were initiated 
by a single cell, I established 15 single cell-derived clonal lines from H-Ras/SV40LT-
transduced AHs, and injected them into the spleen of NOD/SCID mice. Fourteen out of 
15 clones (93.3%) showed comparable frequency of engraftment and kinetics of tumor 
growth. More importantly, the 42 examined tumors displayed overlapping EMT-CCA-
HCC-like phenotypes indistinguishable from the tumors initiated by a bulk of H-
Ras/SV40LT-transduced AHs (Figure 24).  
  
Figure 24. Schematic overview of the strategy and representative hematoxylin-eosin 
staining of tumors derived from single cell clones of H-Ras/SV40LT-transduced 
adult hepatocytes. Liver tumors were generated by intrasplenic injection of 15 single 
cell-derived clonal lines established from H-Ras/SV40LT-transduced adult hepatocytes. 
a, b, and c denote HCC-, CCA-, and EMT-like areas within the same tumor. Scale bar = 







 I concluded that upon oncogenic transformation, murine HPCs, HBs, and AHs 
were capable of propagating liver cancers of multilineage differentiation closely resem-
bling human PLCs, and that the differentiation stage of cell-of-origin had a profound ef-
fect on tumor phenotype. 
4.1.4  Common activation of epithelial-mesenchymal transition-related 
pathways during oncogenic reprogramming of hepatic lineage cells 
Next, I analyzed the transcriptome of the tumors described above (10 HPC-, 20 
HB-, and 20 AH-derived) and freshly isolated mouse HPCs, HBs, and AHs (4 samples 
each) to define key molecular similarities and differences between tumors and corre-
sponding cell-of-origin. Using bioequivalence test, I found that tumor groups displayed 
higher degree of similarity to each other than to their cell-of-origin (Figure 25). Notably, 
HPC-derived tumors showed the highest (71%) and AH-derived tumors the lowest (53%) 
level of similarity to their normal counterparts suggesting that reprogramming of mature 
hepatocytes into tumor-initiating cells required more substantial genomic changes as 
compared to HBs or HPCs.  
 
Figure 25. Bioequivalence test of similarities between HPC-, HB-, and AH-derived 
tumors and their respective cell of origin. Liver tumors were generated by intrasplenic 
injection of H-Ras-EGFP+/SV40LT-mCherry+ HPCs, HBs, and AHs. Molecular similar-
ities between tumors (10 HPC-, 20 HB-, and 20 AH-derived) and freshly isolated mouse 
HPCs, HBs, and AHs (4 samples each) were identified by bioequivalence test. Data were 







I identified 590 genes with significant common dysregulation (409 up- and 181 
downregulated genes) among the three tumor groups (Figure 26) by bootstrap t-test. Re-
markably, hierarchical clustering of common genes separated the tumors according to 
their cell-of-origin with HPC tumors clustered more closely with HB than AH tumors 
(Figure 27).  
 
Figure 26. Venn diagram of differentially expressed genes. Genes with significantly 
different expression in HPC-, HB-, and AH-derived tumors compared to their normal 
counterparts were identified by bootstrap t-test using 5000 repetitions; P < 0.001; fold 
change > 2. 
 
Figure 27. Supervised hierarchical clustering of HPC-, HB-, and AH-derived tumors 
based on 590 commonly differentially expressed genes. Genes with significant com-
mon dysregulation among HPC-, HB-, and AH-derived tumors were identified by boot-
strap t-test. Red and green colors represent up-and downregulation of genes, respectively. 
Note the clear separation of tumors based on their cell-of-origin, suggesting dysregulation 







A significant proportion of common genes were associated with EMT, consistent 
with the highly metastatic nature of all three tumor groups. In particular, I found a drastic 
upregulation of Zeb2, Vim, Mmp12, Mmp13, Pdgfra, Pdgfrb, Ednra, and Flt1, which was 
also confirmed by qRT-PCR (Figure 28).  
 
Figure 28. Upregulation of EMT-related genes in HPC-, HB-, and AH-derived tu-
mors. Box-plots represent the expression level of commonly changed EMT genes in 
HPC-, HB-, and AH-derived tumors and corresponding normal cells based on microarray 
(white graphs) and quantitative reverse transcription polymerase chain reaction (qRT-
PCR) data (grey graphs). Six samples of each tumor group and their normal counterparts 
(3 samples each) were analyzed in triplicates by qRT-PCR, and mRNA expression of 
target genes were normalized to Gapdh. Significant differences were calculated by Mann-
























































































































































































































































































































































































































































































































 I further revealed a significant enrichment of a 35-gene EMT-signature in HPC-
, HB-, and AH-derived tumors using GSEA (Figure 29).172  
 
Figure 29. Gene set enrichment analysis using a curated 35-gene EMT signature. 
Enrichment plots displaying significant enrichment of EMT-related genes in HPC-, HB-
, and AH-derived tumors. The EMT gene signature was obtained from the Molecular 
Signatures Database 3.0.172 NES, normalized enrichment score; P < 0.05 was considered 
significant.         
4.1.5  Hepatic lineage stage determines the transcriptional programs re-
quired for oncogenic reprogramming  
In total, 12 claudin genes (Cldn1-7, Cldn9, Cldn11, Cldn12, Cldn14, and Cldn23) 
were significantly dysregulated in HPC-, HB-, and AH-derived tumors, however, none of 
these claudins were commonly up- or downregulated among the three tumor groups. All 
of the differentially expressed claudins except Cldn14 were downregulated in HPC-
derived tumors, which might be related to their predominant sarcomatous appearance. 
Notably, AH-derived tumors showed a drastic upregulation of Cldn6 (1135.20-fold), a 
specific marker for mouse pluripotent stem cells (Table 9).189 
Clear separation of mouse liver tumors based on their cell-of-origin by hierar-
chical clustering suggested that distinct hepatic lineage cells dysregulate cell-type-spe-
cific transcriptional programs in response to the same oncogenic stimuli. AH-derived tu-
mors showed the largest number of differentially expressed unique genes compared to 
their cell-of-origin (2826 versus 574 and 906 genes in HB- and HPC-derived tumors, 
respectively) by bootstrap t-test (Figure 26). In addition, network analysis of significantly 
changed, tumor-group-specific genes identified a higher number of transcription factors 
with a predicted activation status in AH-derived tumors (e.g., E2f1, Klf6, Myc) compared 







Table 9. Differentially expressed claudin genes in HPC-, HB-, and AH-derived tu-
mors  
Gene symbol HPC HB AH 
Cldn1 - -20.46 -11.61  
Cldn2 -7.01 12.90 - 
Cldn3 -11.83 7.39 -2.10 
Cldn4 -178.42 2.60 36.06 
Cldn5 - 5.07 - 
Cldn6 -2.42 5.44 1135.20 
Cldn7 -4.80 3.72 - 
Cldn9 - -3.63 -3.61 
Cldn11 - - 70.68 
Cldn12 -4.58 - -3.86 
Cldn14 5.30 - - 
Cldn23 -42.00 7.47 25.90 
Values represent fold change of claudin gene expression between HPC-, HB-, and AH-
derived tumors and their their normal counterparts based on microarray.  
To evaluate hepatic-lineage-stage-specific transcriptional memory in HPC-, HB-, 
and AH-derived tumors, I performed GSEA using a hepatocyte-derived iPSC signature 
of 786 genes.190, 191 The signature was significantly enriched in AH- (P < 0.001) but not 
in HB- or HPC-derived tumors (Figure 30).  
 
Figure 30. Gene set enrichment analysis using a hepatocyte-derived induced plu-
ripotent stem cell gene signature of 786 genes.191 Enrichment plots displaying signifi-
cant enrichment in AH- but not in HB- or HPC-derived tumors. P < 0.05 was considered 
statistically significant. 
This provides additional evidence that AHs are indeed the cells of origin of AH-







reprogramming of mature hepatocytes into CSCs. In support of this notion, AH-derived 
tumors showed the highest overlap with a 335-gene ESC core module map (42.1% versus 
19.7% and 22.7% in HB- and HPC-derived tumors, respectively; Figure 31).170  
 
Figure 31. Overlap of differentially expressed genes with a 335-gene embryonic stem 
cell core module map.170 Genes with significantly different expression in HPC-, HB-, 
and AH-derived tumors compared to their normal counterparts were identified by boot-
strap t-test using 5000 repetitions; P < 0.001; fold change > 2. 
Significantly, AH-derived tumors showed a strong upregulation (21.10-fold) of 
Myc, a major link between ESCs and cancer, within the overlapping ESC core genes, 
while Myc expressed at a lower level in HB- and HPC-derived tumors compared to their 
normal counterparts (Figure 32).192 Gene set enrichment analysis using a list of 229 E-
box containing c-Myc target genes confirmed that the target genes were significantly en-
riched in AH- (P < 0.0001) but not in HPC- or HB-derived tumors (Figure 33).173  
From these results, c-Myc signaling emerges as a major AH-specific component 
of the transcriptional signature induced upon H-Ras/SV40LT-driven transformation in 
concordance with a previous finding that c-Myc is a driver gene of  malignant conversion 










Figure 32. Expression of c-Myc in mouse hepatic lineage cell-derived tumors. Box 
plots illustrate mRNA expression of Myc in HPC-, HB-, and AH-derived tumors and their 
normal counterparts based on microarray data. Significant differences were calculated by 
Mann-Whitney U test. P < 0.05 was considered statistically significant. *P < 0.05; **P < 
0.01. (Inset) Western blot analysis of c-Myc protein expression in primary AHs and AH-
derived tumors. Actin was used as loading control. 
 
Figure 33. Cell type-dependent activation of Myc-regulated gene networks in tumors 
initiated by H-Ras/SV40LT-transformed distinct hepatic lineage cells. Gene set en-
richment analysis showing significant enrichment of c-Myc Ebox-target genes in AH-
derived tumors. The 229-gene list of c-Myc Ebox target genes was obtained from the 
Molecular Signatures Database 3.0.173 P < 0.05 was considered significant. 
4.1.6  Myc is required for H-Ras/SV40LT-mediated oncogenic repro-
gramming of adult hepatocytes 
To substantiate the role of c-Myc in transformation of adult hepatocytes, I carried 
out c-Myc loss-of-function experiments in AHs transduced with H-Ras/SV40LT. I used 
a retroviral vector expressing shRNA to achieve stable and effective knockdown of c-







cell clone that showed the most efficient (more than 90%) c-Myc protein knockdown 
(Figure 34). Cells stably expressing a scrambled target sequence were used as control. 
 
Figure 34. Efficient knockdown of c-Myc expression in H-Ras/SV40LT-transduced 
AHs. For stable knockdown of c-Myc, H-Ras-EGFP+/SV40LT-mCherry+ AHs were 
transduced with pRS retroviral vectors expressing c-Myc shRNA or scrambled shRNA. 
Myc protein level was detected by western blotting, non-infected AHs or AHs transduced 
with scrambled shRNA were used as negative control. Expression of actin was used as 
loading control. Asterisk marks the cell clone subjected to cancer stem cell assays. 
 Knockdown of c-Myc expression significantly reduced the number of CD133+ 
cells (1.5% compared with 21.4% in control cells transduced with scrambled shRNA) 
(Figure 35), decreased the frequency of SP cells (0.07% compared with 0.46% in control 
cells) (Figure 36), and diminished sphere forming capacity and sphere size (Figure 37).  
 
Figure 35. Knockdown of c-Myc expression reduces CD133 expression in H-
Ras/SV40LT-transduced AHs. Stable knockdown of c-Myc in H-Ras-EGFP+/SV40LT-
mCherry+ AHs was achieved using a retroviral vector expressing c-Myc shRNA. Expres-
sion of CD133 was analyzed by flow cytometry, AHs transduced with scrambled shRNA 
were used as control. Blue line indicates CD133-APC, red line corresponds to staining 
















Figure 36. Knockdown of c-Myc reduces the size of side population in H-
Ras/SV40LT-transduced AHs. Stable knockdown of c-Myc in H-Ras-EGFP+/SV40LT-
mCherry+ AHs was achieved using a retroviral vector expressing c-Myc shRNA. Side 
population cells were identified by Hoechst 33342 (HO) staining, AHs transduced with 
scrambled shRNA were used as control. Side population gates were set up by using 
the fumitremorgin C inhibitor samples (dot plots shown at the bottom). Data represent 
mean ± standard deviation of triplicate measurements. 
        
Figure 37. Knockdown of c-Myc expression diminishes sphere forming capacity and 
sphere size in H-Ras/SV40LT-transduced AHs. H-Ras-EGFP+/SV40LT-mCherry+ AHs 
expressing c-Myc shRNA or scrambled shRNA were seeded in 1% methylcellulose in 
ultra-low attachment 96-well plates at low density. Spheroids were counted after 7 
days. White bars correspond to sphere number, whereas black bars correspond to sphere 
volume. Data represent mean ± standard deviation of four experiments. Significant 
differences were evaluated by Poisson generalized linear model and Student’s t-test. P < 
0.05 was considered statistically significant. ∗∗∗P < 0.001.  
Furthermore, subcutaneous tumor growth in immunodeficient mice was signifi-
cantly reduced in c-Myc shRNA-expressing cells compared to control cells transduced 








Figure 38. Knockdown of c-myc expression reduces subcutaneous growth of H-
Ras/SV40LT-transduced AHs. One hundred cells of H-Ras-EGFP+/SV40LT-mCherry+ 
AHs expressing c-Myc shRNA or scrambled shRNA were injected subcutaneously into 
both flanks of NOD/SCID mice (5 mice/group). Tumor diameters were measured weekly 
by an external caliper. Significant differences were evaluated by Student’s t-test. P < 0.05 
was considered significant. 
4.2  Distinct claudin expression profiles of human HCC and 
metastatic colorectal and pancreatic carcinomas 
4.2.1  Immunohistochemical and morphometric analysis  
I analyzed the expressions of CLDN-1, -2, -3, -4, and -7 in 20 cases of HCCs, and 
liver metastases of 20 colorectal adenocarcinomas and 15 pancreatic adenocarcinomas 
with paired surrounding non-tumorous liver tissues, as well as 5 normal liver samples by 
immunohistochemistry. The results of the morphometric analysis of CLDN immunostain-
ings are presented in Table 10. 
Hepatocellular carcinoma cells arranged in trabecular, glandular or acinar patterns 
revealed moderate apical membrane reactivity for CLDN-1 (Figure 39A). In contrast, the 
membranous staining appeared on the entire circumference of tumor cells in CRLM and 
PLM (Figure 39B, C). In normal and non-tumorous livers, intense apical staining ap-
peared in bile duct cells, whereas hepatocytes exhibited a weak apical positivity (Figure 
39D). Morphometric analysis revealed the highest expression level of CLDN-1 in 
CRLMs (Table 10, Figure 40A). However, the difference in CLDN-1 expression among 
CRLMs, HCCs, and PLMs was statistically significant only when surrounding non-tu-
morous and normal livers were excluded from the Kruskal-Wallis test (Figure 40F; 







Claudin-2 immunostaining showed cytoplasmic, granular positivity in both tu-
morous (Figure 39E-G) and normal cells (Figure 39H). By morphometry, significantly 
lower expression was observed in all three tumor groups compared to surrounding non-
tumorous liver tissue (Figure 40B), where both hepatocytes and bile duct cells exhibited 
intense cytoplasmic staining.  
Significantly increased CLDN-3 membrane staining was detected in CRLMs 
(Figure 39J) compared to HCCs and PLMs (Figure 39I, K; Figure 40C). Ten (66.7%) 
out of 15 PLM samples showed weak, focal positivity (Figure 39K). HCCs and non-
tumorous hepatocytes displayed weak, scattered membrane staining (Figure 39I, L), 
while bile duct cells were strongly positive for CLDN-3 (Figure 39L).  
Tumor cells of all CRLM and PLM samples exhibited a strong membranous stain-
ing pattern for CLDN-4 (Figure 39N, O). Morphometric analysis revealed no significant 
difference in CLDN-4 expression between CRLM and PLM tumor groups (Figure 40D). 
Hepatocellular carcinoma cells (Figure 39M), non-tumorous and normal hepatocytes did 
not express CLDN-4, while we detected weak to moderate membranous expression in the 
bile duct cells of non-tumorous and normal liver (Figure 39P).  
Claudin-7 immunostaining was significantly increased in CRLMs (Figure 39R) 
in comparison with the other groups (Table 10, Figure 40E). In all, 9/15 (60.0%) PLMs 
showed focal, faint reactivity (Figure 39S), and weak membrane staining was present on 
HCC cells and normal hepatocytes (Figure 39Q, T). All normal bile ducts were uniformly 
CLDN-7 positive (Figure 39T). 
In summary, we demonstrated that HCCs are characterized by moderate CLDN-
1 and weak CLDN-2, -3, and -7 expression, whereas do not express CLDN-4. Liver me-
tastases of colorectal adenocarcinomas displayed strong CLDN-1, -3, -4, -7, and weak 
CLDN-2 immunostaining.  Liver metastases of pancreatic adenocarcinomas showed 








Figure 39. Immunohistochemical detection of claudins in HCC, liver metastases of 
colorectal adenocarcinomas (CRLM) and pancreatic adenocarcinomas (PLM), and 
normal liver (NL). (A-D) Claudin-1 in HCC, CRLM, PLM, and NL. (E-H) Claudin-2 in 
HCC, CRLM, PLM, and NL. (I-L) Claudin-3 in HCC, CRLM, PLM, and NL. (M-P) 
Claudin-4 in HCC, CRLM, PLM, and NL. (Q-T) Claudin-7 in HCC, CRLM, PLM, and 
NL. Scale bar = 50 µm. 
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P (K-W)  
P (pairwise comparison) 
 vs CRLM vs PLM vs SL vs NL 
CLDN-1 HCC 1.83 ± 0.41 < 0.001 NS NS NS NS 
 CRLM 5.29 ± 0.88   NS < 0.001 NS 
 PLM 1.45 ± 0.49    NS NS 
 SL 0.67 ± 0.11     NS 
 NL 0.42 ± 0.18      
CLDN-2 HCC 1.35 ± 0.23 < 0.001 NS NS < 0.001 NS 
 CRLM 0.98 ± 0.27   NS < 0.001 NS 
 PLM 1.82 ± 0.39    NS NS 
 SL 4.29 ± 0.18     NS 
 NL 3.33 ± 0.61      
CLDN-3 HCC 0.31 ± 0.07 < 0.001 < 0.001 NS NS NS 
 CRLM 7.61 ± 1.09   < 0.001 < 0.001 0.026 
 PLM 0.79 ± 0.25    NS NS 
 SL 0.45 ± 0.09     NS 
 NL 0.28 ± 0.08      
CLDN-4 HCC 0.00 ± 0.00 < 0.001 < 0.001 < 0.001 0.046 NS 
 CRLM 10.82 ± 0.63   NS < 0.001 0.029 
 PLM 7.16 ± 0.98    < 0.001 NS 
 SL 0.01 ± 0.00     NS 
 NL 0.01 ± 0.00      
CLDN-7 HCC 0.38 ± 0.09 < 0.001 < 0.001 NS NS NS 
 CRLM 9.32 ± 0.93   < 0.001 < 0.001 0.001 
 PLM 0.57 ± 0.20    NS NS 
 SL 0.22 ± 0.05     NS 
 NL 0.10 ± 0.06      
Claudin expression was measured as percentage of immunopositive area by morphome-
try. Data represent mean ± standard error of mean. Expression levels among the groups 
were compared by Kruskal-Wallis and post hoc tests; the surrounding non-tumorous liv-
ers were treated as one group. P < 0.05 was considered statistically significant. K-W, 








Figure 40. Scatter dot plots illustrating the differences in claudin expression evalu-
ated by morphometric analysis. Claudin expression was measured as percentage of im-
munopositive area. Dots represent individual samples; horizontal lines represent mean 
values for each group. Expression levels among the groups were compared by Kruskal-
Wallis and post hoc tests; the surrounding non-tumorous livers were treated as one group. 
Claudin-1 expression was compared including (A) or excluding (F) surrounding non-tu-
























































































































































































4.2.2  Quantitative RT-PCR analysis 
Claudin-1, -2, -3, -4, and -7 mRNA expressions were analyzed in 20 HCCs, 20 
CRLMs, and 20 PLMs with paired SL samples and 5 normal livers. The results of qRT-
PCR analysis are presented in Table 11 and Figure 41.  





P (K-W)  
P (pairwise comparison) 
 vs CRLM vs PLM vs SL vs NL 
CLDN-1 HCC 0.35 ± 0.07 < 0.001 0.012 NS NS NS 
 CRLM 0.11 ± 0.03   NS < 0.001 0.004 
 PLM 0.15 ± 0.02    0.006 NS 
 SL 0.49 ± 0.05     NS 
 NL 0.86 ± 0.25      
CLDN-2 HCC 0.02 ± 0.01 < 0.001 NS < 0.001 < 0.001 NS 
 CRLM 0.03 ± 0.01   0.001 NS NS 
 PLM 0.15 ± 0.03    NS NS 
 SL 0.09 ± 0.02     NS 
 NL 0.09 ± 0.05      
CLDN-3 HCC 0.05 ± 0.01 < 0.001 < 0.001 NS NS NS 
 CRLM 0.27 ± 0.05   0.001 < 0.001 NS 
 PLM 0.05 ± 0.02    NS NS 
 SL 0.07 ± 0.02     NS 
 NL 0.09 ± 0.02      
CLDN-4 HCC 0.01 ± 0.00 < 0.001 < 0.001 0.003 NS NS 
 CRLM 0.08 ± 0.02   NS < 0.001 NS 
 PLM 0.03 ± 0.01    0.024 NS 
 SL 0.01 ± 0.00     NS 
 NL 0.02 ± 0.01      
CLDN-7 HCC 0.02 ± 0.00 < 0.001 NS 0.011 NS NS 
 CRLM 0.03 ± 0.01   < 0.001 < 0.001 NS 
 PLM 0.00 ± 0.00    NS NS 
 SL 0.01 ± 0.00     NS 
 NL 0.01 ± 0.01      
Samples were analyzed in duplicates by qRT-PCR, and mRNA expression of claudins 
was normalized to β-actin. Data represent mean ± standard error of mean. Claudin ex-
pression levels were compared by Kruskal-Wallis and post hoc tests; the surrounding non-









Claudin-2, -3, -4, and -7 showed overall good concordance between their mRNA 
and protein expression patterns indicating that they are regulated largely at the level of 
transcription. However, a striking difference was observed between CLDN-1 mRNA and 
protein expression. Claudin-1 expression was significantly downregulated in CRLM 
when compared with HCC, SL, and normal liver; mRNA expression in PLM was also 
lower than in SL. I detected lower CLDN-2 expression in HCC and CRLM than in SL, 
however, the difference was statistically significant only between HCC and SL. Claudin-
3 and -4 mRNA levels were significantly higher in CRLM than in HCC and SL, expres-
sion of CLDN-3 was also increased in CRLM compared to PLM. Furthermore, I found 
that CLDN-7 mRNA expression was significantly higher in CRLM than in PLM and SL.  
Figure 41.  Differences in claudin mRNA expression. Bar graphs illustrate the relative 
mRNA expression levels of claudin-1, -2, -3, -4, and -7 in HCC, CRLM, PLM, SL, and 
NL by qRT-PCR after normalization to β-actin. Data represent mean ± standard error of 
mean. Claudin expression levels were compared by Kruskal-Wallis and post hoc tests; 
the surrounding non-tumorous livers were treated as one group. Asterisk indicates signif-
icant difference (P < 0.05).  
 
 




















































5.  DISCUSSION 
5.1  Contribution of distinct mouse hepatic lineage cells to the 
evolution of liver cancer stem cells and heterogeneity of HCC 
In the present study, I aimed to explore the contribution of distinct hepatic lineage 
cells to the evolution of liver CSCs and genetic and phenotypic heterogeneity of HCC 
using a mouse model of genetically defined liver cancer.194 I provide for the first time 
direct evidence that diverse hepatic lineage cells from fetal and adult progenitor cells to 
terminally differentiated hepatocytes can be targets for neoplastic transformation and ac-
quire a high degree of genetic similarity through activation of diverse donor-cell-specific 
signaling pathways. 
The origin of CSCs has recently become the focus of intensive research. Multiple 
hypotheses have emerged implicating adult stem cells, adult progenitor cells, differenti-
ated cells, and non-stem cancer cells as the origin of CSCs. Many tissues and organs 
contain a small, dedicated population of undifferentiated adult stem cells (also known 
as tissue stem cells or somatic stem cells) throughout the majority of postnatal life.195 
Adult stem cells reside in a specialized microenvironment, denoted as ‘niche’, that pro-
vides extracellular cues to maintain and regulate stem cells.196 The primary roles of adult 
stem cells are to maintain and repair the tissues where they reside.197 They usually 
remain in a quiescent state until being activated by external stimuli. Adult stem cells, 
like all stem cells, have two hallmark capabilities: the ability to self-renew, and the 
ability to differentiate and generate multiple cell lineages over long periods of time. 
Typically, adult stem cells give rise to an intermediate cell type or types before achiev-
ing a fully differentiated state. This intermediate cell type is referred to as a progenitor 
or precursor cell. Progenitor or precursor cells are partly differentiated cells that are 
committed to differentiating along a particular cellular development pathway.87, 195 No-
tably, some adult stem cells from one tissue possess the ability to generate the differ-
entiated cell types of another tissue; this phenomenon is referred to as ‘plasticity’ or 
‘transdifferentiation’.198, 199 Adult stem cells in tissues with high turnover rate are com-







long lifespan. This creates ideal circumstances for DNA damage to accumulate, which 
is the primary driving force behind cancer initiation.200 
In HCC, CSCs have been identified using several markers, including CD133, 
CD90, CD44, CD24, CD13, oval cell marker OV6, EpCAM, and Hoechst dye efflux or 
aldehyde dehydrogenase activities.80, 83, 201-206 Many of these markers are also expressed 
in normal hepatic stem/progenitor cells. However, despite extensive efforts, the origin of 
CSCs in HCC is not fully elucidated. Several candidates in the hepatocyte lineage includ-
ing adult hepatic stem cells, hepatic progenitor cells, and terminally differentiated hepato-
cytes have been implicated as cellular targets for oncogenic transformation. Adult hepatic 
stem cells reside in the small terminal bile ductules that form the canals of Hering and get 
activated following hepatocyte injury.207 The early descendants of hepatic stem cells are 
called hepatic progenitor cells or oval cells in rodents.183 These cells have the capacity to 
differentiate into both hepatocytes and cholangiocytes. Frequent expression of hepatic 
stem/progenitor cell markers in experimental and human HCCs favors the hypothesis of 
stem/progenitor cell origin at least for some HCCs.178 Human combined hepatocellular 
cholangiocarcinoma (CHC), a rare form of primary liver cancer that displays morpholog-
ical features of both HCC and cholangiocarcinoma, is considered the best example of a 
hepatic stem/progenitor cell-derived tumor.178, 209, 210 On the other hand, expression of 
stem/progenitor cell markers may reflect dedifferentiation of mature hepatocytes or phe-
notypic plasticity of cancer cells. Long life span and remarkable regenerative potential of 
mature hepatocytes strongly support their susceptibility to malignant transformation un-
der selective pressure induced by chronic inflammatory cell death.211 This concept is sup-
ported by various mouse models of hepatocarcinogenesis, especially by those established 
using hydrodynamic gene delivery that predominantly induces genetic alterations in ma-
ture hepatocytes.212, 213 Sequential phenotypic changes in diseased liver, such as emer-
gence of dysplastic foci, nodules, and HCC further supports oncogenic transformation of 
mature hepatocytes.214  
My novel data show that forced expression of oncogenic H-Ras/SV40LT repro-
grams diverse hepatic lineage cells into CSCs as judged by an increase or acquisition of 
(1) CSC/progenitor cell markers (CK19, A6, EpCAM, CD133) and (2) side population, 
(3) activation of EMT- and ESC-like transcriptional programs, (4) long-term self-renewal 







differentiation in various in vivo tumorigenicity assays. My results indicating that com-
mitted progenitor cells and mature hepatocytes can be converted into CSCs and the gen-
erated tumors contain a high proportion of CSCs are in accordance with several recent 
studies, thus prompting a revision of the canonical stem cell/CSC concept. The classical 
stem cell and CSC models suggest that rare, relatively quiescent stem cells/CSCs reside 
at the apices of hierarchies and differentiate into nonstem progeny in a unidirectional 
manner. However, several lines of evidence indicate that stem cells/CSCs are not neces-
sarily rare or quiescent and are regulated by niche signals following neutral competition 
dynamics.215 In intestinal crypts, up to 10 percent of crypt cells are intestinal stem cells 
expressing Lgr5.216 Adult stem cells can actively divide throughout life in many tissues, 
such as intestinal crypts and stomach pylorus.216, 217 Stem cell hierarchies can display a 
cellular plasticity more widespread than previously thought, meaning that progenitor cells 
and differentiated cells are able to re-enter the niche and undergo reprogramming to re-
place lost stem cells.215 For example, Dll1+ secretory progenitor cells and Alpi+ entero-
cyte-lineage progenitors in the mouse intestine acquire stem cell functions and replace 
lost Lgr5+ stem cells in response to tissue damage.218, 219 In mouse trachea, luminal secre-
tory cells can revert into functional stem cells upon the ablation of airway stem cells. 
Notably, the tendency to dedifferentiate is inversely correlated to the maturity of the se-
cretory cell.220 Furthermore, terminally differentiated hepatocytes can enter the cell cycle 
to replace lost tissue during liver regeneration without reverting back to a stem cell-like 
state.221  
In concordance with recent findings that associate EMT, stem cell traits, and can-
cer, my genome-wide expression analysis revealed a significant upregulation of EMT- 
and ESC-related genes in HPC, HB, and AH tumors compared to their respective cell of 
origin.173, 174, 222 EMT is a biologic process that allows epithelial cells to acquire a mesen-
chymal cell phenotype with an enhanced migratory capacity, invasiveness, and increased 
resistance to apoptosis.223 Several studies have demonstrated a direct link between EMT 
and the gain of epithelial stem cell properties. Mani et al. reported that overexpression of 
the transcription factors Snail or Twist in human mammary epithelial cells not only in-
duced EMT, but also led to the acquisition of stem cell properties.92 Moreover, stem-like 
cells isolated either from mouse or human mammary glands or mammary carcinomas 







of EMT in transformed human mammary epithelial cells promoted the generation of 
CSCs. Notably, CSCs may exist in an intermediate state of EMT and can transition be-
tween epithelial and mesenchymal states.224, 225 Using epithelial lineage tracing, Rhim et 
al. demonstrated that a small population of PDAC cells displayed features of an interme-
diate stage of EMT, co-expressing the EMT marker Zeb1 or Fsp1, and the epithelial 
marker E-cadherin, whereas 42% of cancer cells completed an EMT. Furthermore, they 
found that a large fraction of circulating pancreatic cancer cells maintained a mesenchy-
mal phenotype in the circulation and stained positive for putative pancreatic CSC markers 
CD24 and CD44. When PDAC cells were separated according to their EMT status (i.e., 
partial or complete EMT) and transplanted into the pancreas, the generated tumors were 
similar with respect to their mesenchymal and epithelial composition. Collectively, these 
studies indicate that cancer cells passing through EMT acquire stem cell properties.  
 Similar to my findings, recent work has shown generation of CSCs by oncogenic 
reprogramming of human fibroblasts.226 Plasticity of both normal and neoplastic non-
stem cells was neatly demonstrated by Chaffer et al.227 They identified a subset of basal-
like human mammary epithelial cells that spontaneously dedifferentiated into stem-like 
cells, and generated cancer stem-like cells upon transformation by SV40 early region and 
H-Ras. Moreover, they described that non-stem cancer cells also underwent spontaneous 
conversion and gave rise to CSC-like cells in vitro and in vivo. Gupta et al. provided 
further evidence that both CSCs and non-stem cancer cells exhibit plasticity and are ca-
pable of undergoing phenotypic transitions in response to certain stimuli.228 Cellular sub-
populations displaying luminal, basal or stem-like phenotypes were purified from two 
human breast cancer cell lines. Over time, each isolated subpopulation of cells returned 
towards equilibrium proportions of the parental cell lines by generating cells of the other 
two phenotypes. Notably, CSC-like cells arose from non-stem luminal or basal cells de 
novo. The interconversion between cell states occurred in a stochastic manner, irrespec-
tive of the phenotype of the isolated subpopulation. The luminal and basal subpopulations 
also regenerated functional stem-like cells in vivo when certain environmental stimuli 
were modified, and the proportions of luminal, basal, and stem-like cells in the tumors 
were comparable. Thus, convergence toward equilibrium proportions could be occurring 
because of cell-state interconversion within tumors.  







that can be acquired at any stage of cellular differentiation, rather than as an intrinsic 
property acquired only on a cell's formation. The bidirectional interconversion between 
neoplastic stem and non-stem cell populations holds important implications for therapeu-
tic strategies to eradicate cancer. If non-CSCs can spontaneously convert into CSCs, then 
anticancer therapies that target exclusively CSCs are not likely to be effective because 
non-CSCs would replace the eradicated CSCs after cessation of therapy, leading to re-
newed tumor growth. Therefore, anti-CSC agents should be combined with therapeutic 
agents that target the non-CSCs population within the tumors. Alternatively, combination 
of anti-CSC agents with agents that block conversion of non-CSCs into CSCs is required 
for durable clinical benefit. These clinical implications have been highlighted in a recent 
study by de Sousa e Melo et al.229 They demonstrated that depletion of Lgr5+ CSCs 
restricted primary tumor growth in a mouse model of colorectal cancer, but did not led 
to tumor regression. Instead, tumors were maintained by proliferating Lgr5- cells that 
continuously attempted to replace Lgr5+ CSCs in a way reminiscent of the plasticity 
observed in normal intestine upon Lgr5+ stem cell depletion.218, 219 Notably, depletion 
of Lgr5+ CSCs in primary tumors or in established liver metastases resulted in substantial 
decrease in liver metastatic burden, suggesting that the functional contribution of CSCs 
during colorectal carcinogenesis was influenced by tissue location and tumor microen-
vironment.229  
I demonstrate that irrespective of the hepatic lineage hierarchy, H-Ras/SV40LT-
transduced cells are capable of multilineage differentiation and give rise to tumors with 
varying contribution of EMT-, CCA-, and HCC-like phenotypes. My novel findings sug-
gest that hepatic lineage cells at distinct differentiation stages can be the cell of origin of 
not only HCC but also of other types of PLC, such as CCA and CHC. Human PLCs are 
pheno- and genotypically highly heterogeneous.177 Cholangiocarcinoma is the second 
most common type of PLC with increasing incidence worldwide.230 Cholangiocarcinoma 
is classified according to its anatomical location along the biliary tree into three subtypes: 
intrahepatic, perihilar, and distal CCA. Tumors of different locations display pronounced 
heterogeneity, implicating potential diverse cellular origins in each CCA subtype. In ac-
cordance with my results, CD34+ CSCs isolated from a human HCC cell line generated 
HCC, CCA, and CHC in immunodeficient mice, supporting the concept that primary liver 







with distinct antigenic profiles determined the types of PLC that would be generated in 
the xenograft assay, indicating the contribution of liver CSC heterogeneity to the hetero-
geneity of PLC. However, this study did not directly address the origin of CD34+ liver 
CSCs but assumed that these CSCs originated from CD34+ hepatic stem cells. 
One of the most intriguing findings of my study is that mature hepatocytes can 
give rise to CCA. This is supported by several studies that suggest that hepatocytes can 
convert into biliary epithelial cells in response to acute and chronic biliary injury.232-236 
Michalopoulos et al. have demonstrated that chronic biliary injury in rats with chimeric 
livers carrying the hepatocyte marker dipeptidyl peptidase IV (DPPIV) leads to an in-
creased number of DPPIV-positive biliary ductules. The frequency of biliary ductules 
derived from DPPIV-positive hepatocytes was dramatically enhanced by pretreatment 
with the biliary toxin methylene diamiline, indicating a large-scale conversion of hepato-
cytes into biliary ductules when the proliferative capacity of the biliary epithelium was 
compromised by toxic injury.232  Using a dynamic lineage tracing approach, Yanger et al. 
have recently reported that activation of Notch, a signaling pathway that regulates biliary 
differentiation during liver development and in adult liver, is sufficient to reprogram 
hepatocytes into biliary epithelial cells in injured liver. Furthermore, lack of functional 
Notch signaling inhibited the generation of hepatocyte-derived biliary epithelial cells af-
ter injury.234 Importantly, lineage tracing analyses have confirmed that thioacetamide-
induced intrahepatic CCA is derived from hepatocytes through Notch-mediated conver-
sion of hepatocytes into biliary lineage cells.237 Forced expression of the Notch1 intracel-
lular domain in mouse hepatocytes as well as forced co‑activation of Notch and Akt sig-
naling pathways using hydrodynamic gene delivery not only induced biliary lineage cells 
but also resulted in the development of intrahepatic CCA, supporting the concept that 
reprogramming of hepatocytes into biliary epithelial cells could lead to CCA develop-
ment.238, 239 In contrast to my findings, adult hepatocytes gave rise to only CCAs in these 
mouse models, whereas H-Ras and SV40LT induce the development of tumors with 
EMT-, CCA-, and HCC- like phenotypes. Since Notch is a major regulator of biliary 
differentiation, this difference could be related to the nature of the transforming agent, 
suggesting that different transforming stimuli may define directions of differentiation in 
the same target cell. In my mouse model, I used oncogenic H-Ras and SV40LT as trans-







function of both p53 and Rb.240 The major tumor suppressor p53 has been extensively 
studied since its discovery in 1979.241 Notably, conditional deletion of p53 in murine liver 
induces tumors with a mixed HCC/CCA histology.242 A recent study by Tschaharganeh 
et al. provided compelling evidence that p53 restricts cellular plasticity and tumorigenesis 
in liver cancer through transcriptional repression of Nestin.243 Expression of nestin, an 
intermediate filament protein that is expressed in a variety of stem and progenitor cells, 
was restricted by p53 in an Sp1- or Sp3-dependent manner. Moreover, loss of p53 facili-
tated dedifferentiation of mature hepatocytes into hepatic progenitor-like cells, which 
generated HCCs or intrahepatic CCAs in response to additional oncogenic hits that target 
Wnt and Notch signaling pathways, respectively. These results again confirm the im-
portance of cellular reprogramming of mature hepatocytes into a stem/progenitor cell 
state during the generation of PLCs. Although it remains unclear whether human CCA 
also originates from adult hepatocytes, these intriguing findings may explain why patients 
with viral hepatitis often develop intrahepatic CCA.244 
Nonetheless, the nature of target cells may have a profound effect on susceptibility 
to oncogenic transformation, tumor histopathology, and global gene expression profiles. 
Thus, the same oncogenic alterations yielded a significantly higher frequency of tumor-
initiating cells among transduced HPCs compared to HBs and AHs. Similarly, Cozzio et 
al. reported that the leukemogenic MLL-ENL fusion gene introduced by retrovirus trans-
formed both hematopoietic stem cells and committed myeloid progenitor cells with high-
est efficiency in the hematopoietic stem cell population.245 In a study of target cells and 
oncogene dosage, a higher dosage of MLL-AF9 was necessary for transformation of com-
mitted myeloid progenitors as compared to hematopoietic stem cells.246 A more striking 
difference was described in the study by Heuser et al., in which only common myeloid 
but not committed progenitors could be transformed by meningioma 1 gene.247 The find-
ings of these experiments strongly suggest that the cell of origin affects the efficiency of 
oncogenic transformation, and susceptibility to transformation is decreasing as cells dif-
ferentiate. In my study, the relatively small differences in the frequency of tumor-initiat-
ing cells among transduced HPCs, HBs, and AHs may be attributed to the strong trans-
forming potential of oncogenic H-Ras and SV40LT that diminishes the differences in the 







Likewise, the differentiation state of the cell of origin influenced the histopathol-
ogy of the resulting tumors. Even though all transformed hepatic lineage cells initiated 
liver cancer with EMT-, CCA-, and HCC-like phenotypes, the frequency of each pheno-
type was very variable in tumors with different cell of origin. Tumors initiated by mature 
AHs displayed a predominant HCC-like phenotype, suggesting that tumorigenic cells re-
tained at least part of the differentiation program characteristic of the original cells. More-
over, a hepatocyte-derived iPSC signature was enriched only in AH but not in HPC or 
HB tumors, indicating the existence of a hepatic-lineage-stage-specific transcriptional 
memory in AH tumors.190, 191 Hepatoblast-derived tumors exhibited a prominent presence 
of CCA-like phenotype, whereas HPC-derived tumors adopted a more primitive mesen-
chymal-like state. This is consistent with recent findings that histological diversity in hu-
man CCA may reflect the differences in cholangiocyte phenotypes that initiate the corre-
sponding tumors.248 Thus, the phenotypic features of primary liver tumors may have roots 
in the origins of the cells that underwent oncogenic transformation.  
Consistent with this, global gene expression analysis clearly distinguished tumors 
of different cells of origin, indicating that distinct genetic alterations are involved in the 
process of malignant transformation of diverse hepatic lineage cells. Similarly, a compre-
hensive integrative molecular analysis of tumors in The Cancer Genome Atlas has re-
cently revealed that cell-of-origin patterns dominate the molecular classification of ap-
proximately 10,000 specimens representing 33 types of cancer.249 Notably, comparison 
of gene expression profiles among HPC, HB, and AH tumors and their freshly isolated 
normal counterparts revealed drastically more differentially expressed genes in AH tu-
mors than in HB or HPC tumors. Furthermore, the highest number of activated ESC-
related genes was found in AH tumors. Within this group of genes, Myc stood out with a 
remarkable 21-fold upregulation that was associated with coordinated activation of Myc-
centered interaction networks. MYC is one of the most commonly activated oncogenes 
involved in human carcinogenesis. The MYC gene encodes the transcription factor c-Myc 
that is involved in the regulation of 15% of genes in the human genome associated with 
diverse biological processes, such as cell growth, apoptosis, and metabolism.250, 251 The 
transcription factor c-Myc is also reported to be an essential regulator of self-renewal and 
pluripotency in ESCs and iPSCs.252, 253 Although the central role of c-Myc in hepatocar-







key player in the oncogenic reprogramming of AHs linked to activation of an ESC-like 
transcriptional program.193, 254, 255 I validated these findings by stable knockdown of c-
Myc in H-Ras/SV40LT-expressing AHs, which significantly reduced the frequency of 
CSCs and delayed tumor growth in immunocompromised mice. In accordance with my 
results, low level of forced c-Myc expression caused upregulation of pluripotency and 
stemness genes NANOG, OCT4, BMI1, SOX2, and EpCAM, and also markedly in-
creased the frequency of SP cells and promoted tumorigenicity in human liver cancer cell 
lines. Notably, c-Myc induced CSC phenotype in a p53-dependent manner.256  
In conclusion, my study provides the first comprehensive and systematic compar-
ison of genetically defined liver carcinomas initiatiated by mouse hepatic lineage cells at 
different stages of differentiation. Mature hepatocytes, committed hepatoblasts, and adult 
hepatic progenitor cells were isolated at high purity and efficiently transduced ex vivo 
with lentiviral vectors expressing oncogenic H-Ras and SV40LT. This allowed a unique 
and direct side-by-side comparison of cellular and molecular characteristics of trans-
formed cells both in vitro and in vivo. I formally demonstrated that any hepatic lineage 
cell can be reprogrammed into CSC by activating diverse cell-type-specific pathways. I 
identified common and cell-of-origin-specific phenotypic and genetic changes that dif-
ferentiated murine tumors according to their origin. Identification of normal cells that can 
transform into CSCs and relevant molecular pathways is essential for a deeper under-
standing of the biology of PLC and development of novel therapeutic approaches for tar-
geting CSCs. It may also allow earlier detection of PLCs and may lead to preventive 
therapies for high-risk individuals. 
5.2  Distinct claudin expression profiles of human HCC and 
metastatic colorectal and pancreatic carcinomas 
In the present study, I sought to analyze the protein and mRNA expression of 
CLDN-1, -2, -3, -4, and -7 in human HCC, CRLM, and PLM. For the first time, I demon-
strate that the examined primary and metastatic neoplasms of the liver display distinct 
claudin expression profiles. HCC is characterized by moderate CLDN-1 and weak 
CLDN-2, -3, and -7 expression, however, does not express CLDN-4. CRLM shows strong 







CLDN-4, moderate CLDN-2, and weak CLDN-1, -3, and -7 stainings.  
Claudins, the major components of epithelial cell tight junctions, exhibit highly 
tissue- and cell-specific expression patterns. They play a critical role in cell adhesion, 
polarity and paracellular permeability. Claudin-1-deficient mice die within one day of 
birth accompanied by excessive water loss from the skin, whereas overexpression of 
certain claudins in vitro alters Na+ permeability.257-259 Claudins have recently been 
recognized as signaling proteins that are functionally associated with various signal 
transduction pathways including proto-oncogene c-Yes, protein kinase A, protein kinase 
C, Rho, PI3K, and MAPK signaling.108, 124, 260 Claudins are tightly regulated by multiple 
molecular mechanisms, and deregulated CLDN expression directly results in several 
distinct abnormalities in cellular physiology.100, 261  
Claudins are often dysregulated in epithelial malignancies, coinciding with tumor 
initiation and progression.262 It has been shown that CLDN dysregulation can occur at 
both transcriptional and post-transcriptional levels.263-265 Tumor development and meta-
static dissemination are frequently associated with a continuous decrease of CLDN ex-
pression and consequent disruption of cell-cell adhesion and cell polarity.266-272 In 
contrast, upregulated CLDN expression has also been reported in various cancer types, 
albeit the functional significance of CLDN overexpression in carcinogenesis is not well 
established. Several lines of evidence have demonstrated that CLDNs play a role in the 
process of EMT. Overexpression of Snail in cultured mouse epithelial cells induced EMT 
with concomitant repression of CLDN-3, -4, and -7 mRNA and protein expression.273 
Interestingly, some CLDNs induce EMT and promote cancer cell invasion and metastatic 
progression, whereas others function to sustain an epithelial phenotype.274-276 In the first 
part of the thesis, I demonstrated that, in accordance with other studies, activation of the 
EMT program is involved in the generation of CSCs. The recently identified claudin-low 
molecular subtype of breast cancer is characterized by low expression of adherens and 
tight junction proteins, such as E-cadherin, CLDN-3, -4, and -7. Notably, this subtype is 
associated with poor prognosis and chemoresistance, expresses stem cell and EMT mark-
ers, and is enriched in CD44+/CD24-/low breast CSCs. Similarly, downregulation of 
CLDN-3, -4, and -7 genes was observed in breast CSCs generated through TGF-β/TNF-
α-mediated EMT in mouse mammary carcinoma cells, suggesting a strong association 







CLDNs in the regulation of CSCs has also been demonstrated in other cancer types.261 
Gene expression profiling has revealed that CLDN-1 is significantly upregulated in 
CD133+/CD117+ ovarian CSCs compared to non-stem cancer cells.281 The same group 
described that microRNA (miRNA)-155 negatively regulates CLDN-1 in ovarian CSCs 
both in vitro and in vivo.282 However, overexpression of miRNA-155 enhanced the mi-
gration and invasive ability of colorectal cancer cells through upregulation of CLDN-1 
expression.283 Short hairpin RNA-mediated knockdown of CLDN-4 in ovarian cancer 
cells delayed spheroid formation, a key feature of CSCs.284 Others have reported that 
miRNA-1275 inhibits the expression of CLDN-11 in glioblastoma CSCs, which represses 
the proliferation of CSCs.285 In colorectal cancer, CLDN-2 promotes self-renewal of 
CSCs and regulates the expression of 9 miRNAs known to control stem cell signaling. 
Among these miRNAs, decrease of miRNA-222-3p expression is essential for the pro-
motion of self-renewal by CLDN-2.286 
Several CLDNs have been associated with the activation of matrix metalloprotein-
ases, promoting the migration of cancer cells cell by degradation of the extracellular ma-
trix.287-289 Significant disorganization of TJ strands and increased paracellular permeabil-
ity were observed in colorectal tumors despite upregulation of CLDN-1, -3, and -4, indi-
cating that CLDN overexpression compromises TJ barrier function and thus may have 
other effects on cellular homeostasis.290 Increased paracellular permeability may also fa-
cilitate the access of cancer cells to nutrients and growth factors critical for tumor growth 
and survival. Furthermore, unique CLDN expression profiles of various cancers are rec-
ognized to carry differential diagnostic, prognostic, and therapeutic potential. Claudin 
immunostaining can aid in the differential diagnosis between mesothelioma and meta-
static adenocarcinoma of the pleura as malignant mesotheliomas have lower expression 
of CLDN-1, -3, -4, -5, and -7, than adenocarcinomas.291 Among the different histologic 
subtypes of lung cancer, adenocarcinomas express higher levels of CLDN-3, -4, and -7 
compared to squamous cell carcinomas, whereas they differ only in CLDN-2 expression 
as compared to small cell lung cancers.128 Claudin-1 overexpression confers a good prog-
nosis in squamous cell carcinoma of the lung and in papillary urothelial neoplasms of low 
malignant potential.166, 292 On the other hand, high CLDN-4 protein levels in low-grade 
urothelial cell carcinomas are associated with significantly shorter recurrence-free sur-







shorter disease-free survival.293  
Claudin-1 is one of the most frequently dysregulated CLDNs in human cancer, 
and its role in carcinogenesis has been thoroughly investigated. I report definite CLDN-
1 positivity in both primary HCC and metastatic tumors, implicating the involvement of 
this protein in hepatocarcinogenesis and metastasis formation. Liver metastases of colo-
rectal adenocarcinomas expressed the highest levels of CLDN-1 protein, whereas HCCs 
and PLMs displayed moderate and weak expression, respectively. Depending on the type 
of cancer, CLDN-1 can act as a tumor suppressor or cancer promoting factor. In human 
CRC, a role for CLDN-1 as a promoter of cellular transformation, tumor growth and me-
tastasis has been established by overexpression and knockdown experiments. Claudin-1 
overexpression in CRC cells increased the activity of MMP-2 and MMP-9, whereas inhi-
bition of CLDN-1 expression decreased the expression of mesenchymal markers and ro-
bustly increased E-cadherin expression.294 Singh et al. reported that overexpression of 
CLDN-1 reduced expression of E-cadherin through upregulation of Zeb1 resulting in 
EMT and increased invasion.295 Similarly, CLDN-1 was found to promote TNF-α-
induced EMT and migration in CRC cells.296 In line with this, increased mRNA and pro-
tein levels of CLDN-1 in CRC tissues have been observed in several studies.290, 294, 297-302 
Immunohistochemical analysis of matched normal colonic mucosa, primary CRC tumors, 
and CRC lymph node or liver metastatic lesions revealed a significant linear association 
between CLDN-1 nuclear, cytoplasmic, or membranous staining and tumor progres-
sion.294 Similarly, Kinugasa et al. demonstrated upregulated CLDN-1 protein expression 
in matched CRC and liver metastatic lesions as compared to normal colon samples.302 On 
the contrary, Matsuoka et al. reported decreased CLDN-1 protein expression in both the 
central parts and invasive fronts of colorectal tumors compared to normal colon mucosa, 
with more prominent loss of expression at the invasive fronts than in the central parts. 
Reduced expression of CLDN-1 was associated with poor tumor differentiation, advanced 
stage, and poor prognosis.303 In another study, loss of claudin-1 expression was found to 
be a strong predictor of disease recurrence and poor patient survival in stage II colon 
cancer.269 Similarly, Nakagawa et al. demonstrated that the overall survival rate was sig-
nificantly higher in CRC patients with high CLDN-1 high expression than in patients with 
low expression.304 Interestingly, similarly conflicting results have been reported on 







well-differentiated HCCs compared to surrounding liver tissues, whereas CLDN-1 im-
munostaining was lost in poorly differentiated HCCs. Attenuated CLDN-1 expression 
was associated with increased incidence of portal invasion, and a lower overall survival 
rate after hepatectomy.305 In contrast, significantly elevated CLDN-1 expression was 
found in cirrhosis and HCC developed in cirrhotic liver.306 Bouchagier et al. observed 
increased CLDN-1 expression in HCC and tumor surrounding liver, suggesting that up-
regulaton of CLDN-1 expression is an early event during hepatocarcinogenesis. Increased 
levels of CLDN-1 were associated with early stage, presence of a single tumor nodule, 
small tumor size, and better prognosis.307 Several lines of evidence support a role for 
CLDN-1 as a potent inducer of cancer cell invasion in HCC. Overexpression of CLDN-1 
promoted the acquisition of invasive capacity by activating c-Abl-PKC signaling pathway 
in normal liver cells, while knockdown of CLDN-1 expression inhibited cellular invasion 
in CLDN-1-overexpressing, invasive HCC cells.308 Furthermore, Suh et al. demonstrated 
that CLDN-1 promoted an invasive phenotype in human liver cells by inducing EMT 
through activation of the c-Abl-Ras-Raf-1/ERK1/2 signaling pathway.275 In PDAC, re-
duced CLDN-1 expression levels were observed in poorly differentiated compared to 
well-differentiated tumors. Furthermore, upregulation of Snail and downregulation of 
CLDN-1 were detected in human pancreatic cancer cells after treatment with TGF-β1.309  
Claudin-2 expression is typical of leaky epithelia characterized by high paracellu-
lar permeability.310 Recent evidence suggests the involvement of CLDN-2 in neoplastic 
transformation and tumor progression. Elevation of CLDN-2 expression has been re-
ported in several cancer types, including lung adenocarcinoma, CRC, and gastric can-
cer.299, 311, 312 In stage II/III colorectal tumors, elevated CLDN-2 expression was associ-
ated with poor recurrence-free survival following chemotherapy, underlining the im-
portance of CLDN-2 in the regulation of CSCs.286 Similarly, Dhawan et al. have reported 
that overexpression of CLDN-2 in human colon cancer cells enhances colony formation, 
cell proliferation, and chemoresistance in vitro, and increases tumor growth in xeno-
grafted mice.313 However, my results demonstrate strong CLDN-2 positivity in non-tu-
morous liver tissue, whereas significantly weaker positivity was observed in HCCs, 
CRLMs, and PLMs. Decreased CLDN-2 expression has also been shown in breast cancer 
compared to adjacent non-neoplastic breast tissue, and downregulation of CLDN-2 ex-







Tabaries et al. found that CLDN-2 levels were elevated exclusively in liver metastases of 
breast cancer compared to matched primary tumors. Moreover, CLDN-2 promoted breast 
cancer metastasis to the liver through CLDN-2-mediated interactions between metastatic 
breast cancer cells and primary hepatocytes.315, 316 This suggests that CLDN-2 not only 
participates in the carcinogenesis of these tumors but may also contribute to a metastatic 
phenotype.  
Claudin-3 and claudin-4 are located in close proximity on chromosome 7. 
Whether this genomic arrangement leads to coordinate regulation is unknown, but coor-
dinate expression of these genes has been reported in several normal and neoplastic tis-
sues, and they are often simultaneously overexpressed in various human malignancies, 
including colorectal, gastric, breast, ovarian, uterine, prostate, and gastric cancers.317-319 
In ovarian cancer, CLDN-3 and CLDN-4 have been shown to promote tumorigenesis and 
metastasis.288 However, Shang et al. demonstrated that knockdown of CLDN-3 and 
CLDN-4 enhanced primary tumor growth and metastasis with concomitant downregula-
tion of E-cadherin and activation of β-catenin pathway signaling, suggesting a tumor sup-
pressor role for CLDN-3 and CLDN-4 in ovarian cancer.320 In line with this, loss of 
CLDN-3 and CLDN-4 have been reported to promote EMT in ovarian cancer cells, re-
flected by upregulation of Twist, downregulation of E-cadherin, and activation of the 
PI3K-AKT pathway.274 Importantly, CLDN‐3 and CLDN‐4 proteins have been identified 
as natural receptors for CPE.113 Binding of CPE to tumor cells expressing CLDN-3 or 
CLDN-4 leads to an acute dose-dependent cytotoxic response.321, 322 Thus, CPE may be 
exploited for therapeutic use for CLDN-3 and -4 expressing tumors.323 In my sample set, 
HCC, PLM, and non-tumorous liver cells exhibited weak CLDN-3 positivity. Expression 
of CLDN-3 in PLM is especially intriguing, because no CLDN-3 staining was detected 
in primary PDAC.133 Furthermore, intrahepatic bile duct cancers were also characterized 
by absence or scarcity of CLDN-3.132 Claudin-3 expression might therefore contribute to 
the metastatic phenotype in pancreatic cancer and could also be used to differentiate be-
tween intrahepatic bile duct cancer and PLM. In contrast, I observed strong CLDN-3 pos-
itivity in CRLM samples, and upregulation of CLDN-3 mRNA and protein have already 
been described in primary CRC.290, 319, 324 The functional significance of elevated CLDN-







EGF-mediated increased expression of CLDN-3 increased cell migration and colony for-
mation in CRC cells.325 On the contrary, Ahmad et al. demonstrated a tumor suppressive 
role of CLDN-3 in CRC. Claudin-3 protein was expressed abundantly in normal colonic 
mucosa, but decreased levels were detected in primary CRC and lymph node metastasis. 
Furthermore, loss of CLDN-3 was associated with CRC progression and poor patient sur-
vival. Claudin-3-null mice exhibited increased susceptibility to colon carcinogenesis in 
response to azoxymethane/dextran sodium.326 A similar decrease in CLDN-3 expression 
was observed to promote HCC. Moreover, epigenetic regulation of CLDN-3 involving 
promoter hypermeythylation was reported in both CRC and HCC.327  
I found that both CRLMs and PLMs were strongly positive for CLDN-4 with no 
significant difference between these two groups, underlining its role in the pathogenesis 
of these lesions. In accordance with previous findings, bile duct cells of non-tumorous 
and normal liver were also positive, whereas I did not detect CLDN-4 expression in HCCs 
and non-tumorous hepatocytes.328 My results indicate that the expression of CLDN-4 dif-
ferentiates between adenocarcinoma liver metastases and HCCs. However, CLDN-4 does 
not distinguish between CRLMs and PLMs. Overexpression of CLDN-4 has also been 
observed both in primary colorectal and pancreatic cancers, as well as in pancreatic in-
traepithelial neoplasia, the precursor lesion of pancreatic cancer.319, 321, 329 Interestingly, 
liver metastases of pancreatic cancer exhibited similarly elevated CLDN-4 expression as 
compared to primary tumors.329 To add another layer of complexity, CLDN-4 was asso-
ciated with less differentiated and invasive phenotypes in primary colorectal and pancre-
atic cancers, suggesting its inhibitory effect on invasion and metastasis. Ueda et al. 
demonstrated that decreased expression of CLDN-4 at the invasive front was correlated 
with infiltrating growth pattern, lymphovascular invasion, and metastasis in colorectal 
cancer.271 Similarly, Matsuoka et al. reported loss of CLDN-4 expression at the invasive 
front of CRCs, which was associated with poor tumor differentiation and advanced TNM 
stage.303 Overexpression of CLDN-4 in pancreatic cancer cells reduced invasive potential 
in vitro and reduced lung metastasis burden in vivo.330 By contrast, CLDN-4 expression 
in ovarian epithelial cells was reported to enhance cell invasion by an increase of MMP-
2 activity.288  
Claudin-7 is one of the highly expressed claudins in normal colon and plays an 







majority of CLDN-7 protein is localized at the basolateral membrane in normal intestinal 
epithelial cells. Its knockdown in mice leads to disruption of intestinal architecture, bar-
rier dysfunction, inflammation, and neonatal death.331 Claudin-7 is dysregulated in vari-
ous malignancies, including lung, liver, colorectal, esophageal, pancreatic, prostate, 
breast, and ovarian cancers.124, 128 Increased CLDN-7 levels were detected in primary 
CRC samples, and overexpression of CLDN-7 in CRC cells disrupted cell polarity and 
increased proliferation, and tumorigenicity.332 Interestingly, Kuhn et al. proposed that tu-
morigenic roles of CLDN-7 are exerted in complex with EpCAM, CD44 variant isoforms, 
and tetraspanins.333 Furthermore, CLDN-7 promoted EMT and tumor cell motility, and 
enhanced metastasis formation.276 In concordance with these results, I also observed 
strong immunostaining for CLDN-7 in CRLM samples. However, other authors described 
CLDN-7 as a cancer suppressor. Reduction of CLDN-7 mRNA levels correlates with ve-
nous invasion and liver metastasis but not with lymph node metastasis in CRC.319 Inter-
estingly, downregulation of CLDN-7 mRNA expression was described as an early event 
during colorectal carcinogenesis, whereas its re-expression was frequently detected in 
lymph node metastases; this may also explain CLDN-7 positivity in my CRLM sam-
ples.334, 335 Reduced CLDN-7 expression is associated with metastasis formation in breast 
cancer and squamous cell carcinoma of the esophagus.270, 336 Kominsky et al. have de-
scribed that loss of claudin-7 correlates with histological grade in both ductal carcinoma 
in situ and invasive ductal carcinoma of the breast.266 I detected weak CLDN-7 positivity 
in HCC samples with no significant difference in comparison to non-tumorous and nor-
mal livers, whereas bile duct cells exhibited very strong membranous staining. Interest-
ingly, our research group has previously found elevated CLDN-7 levels in cirrhosis and 
HCCs developed in cirrhotic livers, indicating that certain structural changes in TJs may 
begin before malignant transformation occurs.306 Liver metastases of pancreatic adeno-
carcinomas were negative or exhibited faint, focal positivity for CLDN-7. In normal pan-
creas, CLDN-7 positivity was reported in both ductal and acinar epithelial cells. In ac-
cordance with my results, CLDN-7 protein appeared to be underexpressed in PDACs as 
compared to normal glands with a gradual decline in parallel with the degree of tumor 
differentiation. No association was found between CLDN-7 expression and tumor size, 
the presence of metastatic lymph nodes or patient survival, indicating that CLDN-7 does 







between claudin protein and mRNA expression with two intriguing exceptions. CLDN-1 
and -7 protein levels were lower in HCCs compared to CRLMs, whereas mRNA levels 
were higher or comparable. This raises the possibility of post-transcriptional regulation 
of these claudins that might be mediated by miRNAs.338 Rapid protein turnover may also 
be responsible for this discrepancy. 
Taken together, my results support the role of altered claudin expression in both 
hepatocarcinogenesis and metastasis formation of colorectal and pancreatic cancers. I 
demonstrate here that HCC, CRLM, and PLM display distinct claudin expression profiles 
that may carry great differential diagnostic value. Liver metastasis of colorectal adeno-
carcinoma is characterized by strong positivity for CLDN-1, -3, -4, and -7, HCC is asso-
ciated with CLDN-1 immunostaining and a lack of CLDN-4, and PLM exhibits strong 
CLDN-4 and weak CLDN-1 positivity. My findings suggest a complex and well-regu-
lated system of claudin expression that is distinct in primary and metastatic liver tumors. 
However, the exact role and functional importance of claudin overexpression and claudin 
downregulation in the development of HCC, CRLM, and PLM remain unclear. One plau-
sible mechanism is that altered claudin expression may modify the structure and function 
of tight junction, which could contribute to the malignant potential of affected cells. Fur-
thermore, these claudins might be involved in signaling pathways that play important role 
in cellular transformation. Downregulation of certain claudins has been demonstrated in 
advanced CRCs, but I detected strong claudin expression in CRLMs. Several factors may 
attribute to this difference, including biological selection of cancer cells during tumor 
progression and microenvironmental influence.339 Dedifferentiated primary CRCs have 
been shown to undergo redifferentiation at liver metastases with concomitant re-expres-
sion of the tight junction protein ZO-1, which may also be associated with recovery of 
the claudin phenotype.340 In conclusion, primary hepatocellular carcinoma and metastatic 
colorectal and pancreatic carcinomas exhibit distinct claudin expression profiles. This 
provides further insight into their pathobiology and may aid in differentiating focal liver 
lesions. The observed expression changes indicate that these claudins play a pivotal role 
in the process of carcinogenesis and metastasis formation. Claudins may therefore be 
good candidates for targeted therapy not only in primary liver tumors but also in colorec-







6.  CONCLUSIONS 
In the present study, I demonstrated several novel findings that support the sub-
stantial role of cancer stem cells and their cellular origin in the emergence of heterogene-
ity in hepatocellular carcinoma, and the diagnostic utility of claudin proteins in primary 
and secondary liver cancers. The following conclusions can be drawn from my results:  
 
1. Any cell within the mouse hepatic lineage can be a target of oncogenic reprogram-
ming and acquire cancer stem cell traits; however, hepatic progenitor cells are more 
susceptible to oncogenic reprogramming than more differentiated cells. 
 
2. Oncogenic transformation of distinct mouse hepatic lineage cells may give rise to 
liver cancer of multilineage differentiation resembling human primary liver cancers; 
nevertheless, tumors display distinct phenotypes according to their cell-of-origin; he-
patic progenitor cell-derived tumors show epithelial-mesenchymal transition-like 
phenotype, hepatoblast-derived tumors predominantly exhibit cholangiocarcinoma-
like features, and adult hepatocyte-derived tumors display an HCC-like phenotype. 
 
3. Common activation of epithelial-mesenchymal transition-related pathways and acti-
vation of diverse, hepatic-lineage-stage-specific transcriptional programs contribute 
to oncogenic transformation of distinct mouse hepatic lineage cells. 
 
4. Upregulation of c-Myc in adult mouse hepatocytes is required for acquisition of can-
cer stem cell phenotype. 
 
5. Human hepatocellular carcinoma and liver metastases of colorectal adenocarcinoma 
and pancreatic adenocarcinoma display distinct claudin expression profiles: HCCs 
exhibit moderate claudin-1 and weak or no claudin-2, -3, -4, and -7 expression, liver 
metastases of colorectal adenocarcinoma display strong claudin-1, -3, -4, -7 and mod-
erate claudin-2 positivity, and liver metastases of pancreatic adenocarcinoma show 







7.  SUMMARY 
Human hepatocellular carcinoma (HCC) and liver metastases of colorectal cancer 
(CRLM) and pancreatic cancer (PLM) are major health problems globally. Although can-
cer stem cells, a small subset of tumor cells with stem cell features, and claudins, the 
major components of tight junctions have recently been implicated in their development, 
their complex pathogenesis is still not fully elucidated. The aim of the thesis was to ex-
plore the role of cancer stem cells and claudins in the development of HCC, CRLM, and 
PLM. In the first part of the work, I investigated the contribution of hepatic lineage cells 
at different stages of differentiation to the evolution of liver cancer stem cells and genetic 
and phenotypic heterogeneity of HCC. I showed that all mouse hepatic lineage cells (i.e., 
bipotential hepatic progenitor cells, lineage-committed hepatoblasts, and differentiated 
adult hepatocytes) can be target of oncogenic transformation and give rise to primary liver 
cancer; however, hepatic progenitor cells are more susceptible to oncogenic transfor-
mation than more differentiated cells. I demonstrated that all hepatic lineage cells can be 
reprogrammed into cancer stem cells by activation of epithelial-mesenchymal transition 
(EMT)-related and hepatic-lineage-stage-specific pathways. Notably, c-Myc acts as the 
driver of reprogramming in adult hepatocytes. Furthermore, I showed that tumors origi-
nated from these three independent stages of hepatic lineage cells exhibit the phenotypic 
diversity of HCC and cholangiocarcinoma. Hepatic progenitor cell-derived tumors dis-
played EMT-like phenotype, hepatoblasts were predominantly reprogrammed into chol-
angiocarcinoma-like tumors, whereas adult hepatocyte-derived tumors exhibited a prom-
inent presence of HCC-like phenotype. In the second part of the thesis, I aimed to char-
acterize the claudin expression profiles in human HCC, CRLM, and PLM. I demonstrated 
that HCC, CRLM, and PLM display distinct claudin expression profiles. HCC was char-
acterized by moderate claudin-1 and weak claudin-2, -3, and -7 expression, whereas did 
not express claudin-4. CRLM displayed strong claudin-1, -3, -4, -7 and moderate claudin-
2 positivity, and PLM showed strong claudin-4, moderate claudin-2, and weak claudin-1, 
-3, and -7 staining. In summary, my study yielded multiple novel findings supporting the 
contribution of distinct hepatic lineage cells to the evolution of cancer stem cells and 
genetic and phenotypic heterogeneity of HCC and the diagnostic utility of claudin expres-







8.  ÖSSZEFOGLALÁS 
A humán hepatocellularis carcinoma (HCC), valamint a colorectalis carcinoma 
(CRLM) és a pancreas carcinoma (PLM) májáttétei világszinten jelentős egészségügyi 
problémát jelentenek. Bár kialakulásukban számos vizsgálat felvetette a daganatőssejtek, 
a daganatokban csekély számban jelen lévő őssejtek, és a tight junction típusú sejt-
kapcsoló struktúrák gerincét alkotó claudin fehérjék szerepét, rendkívül összetett patoge-
nezisük még nem tisztázott. Kutatásaim célkitűzése a daganatőssejtek és claudinok 
szerepének vizsgálata volt a HCC, CRLM és PLM kialakulásában. Kutatásaim első ré-
szében azt vizsgáltam, hogy a hepatocyta irányú differenciáció különböző stádiumaiban 
lévő sejtalakok mennyiben járulnak hozzá a HCC-ben előforduló daganatőssejtek és a 
HCC-re jellemző genetikai és fenotípusos heterogenitás kialakulásához. Eredményeim 
szerint egerekben a bipotens hepatikus progenitor sejtekben, hepatocyta irányba elkö-
telezett hepatoblastokban és érett hepatocytákban egyaránt végbemehet malignus 
transzformáció és ennek következtében kialakulhat primer májrák, de a hepatikus pro-
genitor sejtek fogékonyabbak a malignus transzformációra, mint a differenciáltabb 
fenotípusú sejtek. Kimutattam, hogy az összes vizsgált sejtalak átprogramozható da-
ganatőssejtté az epithelialis-mesenchymalis átmenetet szabályozó és különböző sejtspe-
cifikus jelátviteli utak aktivációja révén. Kiemelendő, hogy az érett hepatocyták átprogra-
mozásában vezető szerepe van a c-Myc proto-onkogénnek. Kimutattam továbbá, hogy a 
hepatikus progenitor sejtekből származó tumorok elsősorban sarcomatoid típusúak, míg 
a hepatoblastokból kiinduló tumorok cholangiocarcinomára, az érett hepatocytákból szár-
mazó tumorok HCC-re jellemző szövettani képet mutatnak. Kutatásaim második felében 
a HCC, CRLM és PLM claudin expreszióját tanulmányoztam. Eredményeim arra utalnak, 
hogy a HCC, CRLM és PLM jelentősen eltér egymástól a claudinok expressziós mintáza-
tában. A HCC mérsékelt claudin-1 és gyenge claudin-2, -3 és -7 expressziót mutatott, míg 
a claudin-4 negatívnak bizonyult. A CRLM erős claudin-1, -3, -4, -7 és mérsékelt claudin-
2 pozitivitást, míg a PLM erős claudin-4, mérsékelt claudin-2 és gyenge claudin-1, -3 és 
-7 pozitivitást mutatott. Összefoglalva elmondható, hogy kutatásaim számos új ered-
ménnyel támasztják alá a hepatocyta irányú sejtvonal különböző sejtjeinek fontos 
szerepét a daganatőssejtek és a HCC-re jellemző feno- és genotípus heterogenitás kiala-
kulásában és a claudinok jelentőségét a primer és áttéti májrákok elkülönítésében.
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